gliclazide has been researched along with Diabetes Mellitus, Adult-Onset in 398 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Excerpt | Relevance | Reference |
---|---|---|
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease." | 9.30 | Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019) |
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)." | 9.24 | Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017) |
" In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 9.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
"Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels." | 9.06 | Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988) |
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia." | 8.91 | Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015) |
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 7.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
"To report a case of exposure to gliclazide and ramipril during pregnancy in a patient with diabetes mellitus and hypertension." | 7.75 | Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. ( Akar, M; Kolagasi, O; Sari, F; Sari, R, 2009) |
"The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated." | 7.66 | Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983) |
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status." | 6.71 | Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003) |
"Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world." | 6.67 | Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991) |
"A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high." | 6.53 | Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016) |
"Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D." | 5.51 | Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. ( Aronson, R; Bajaj, HS; Bansal, N; Bhela, JS; Brown, RE; Chu, L; Dhillon, G; Gupta, R; Khandwala, H; Padda, JK; Venn, K, 2022) |
"Vildagliptin is a new drug used to treat diabetes mellitus (DM)." | 5.46 | A case of bullous pemphigoid ınduced by vildagliptin. ( Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G, 2017) |
"Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control." | 5.33 | Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006) |
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease." | 5.30 | Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019) |
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)." | 5.24 | Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017) |
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes." | 5.20 | Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015) |
"Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide." | 5.19 | A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014) |
" In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 5.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
"As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk." | 5.14 | [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
"Over 13 weeks, both repaglinide and gliclazide, when combined with bedtime NPH insulin produce similar significant improvements in glycaemic control (-1%) and similar weight gain." | 5.10 | Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. ( Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV, 2003) |
"In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes." | 5.09 | Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. ( Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P, 2001) |
" Plasma glucose and serum insulin, C-peptide, and proinsulin levels were measured before as well as 1 and 2 h after breakfast in 23 patients with non-insulin-dependent diabetes mellitus and 17 patients with impaired glucose tolerance." | 5.08 | Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. ( Awata, T; Inoue, I; Katayama, S; Negishi, K; Noji, S; Takahashi, K, 1997) |
"Gliclazide has been reported to possess the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels." | 5.06 | Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1988) |
"Gliclazide has been reported to decrease platelet function and to inhibit the progression of diabetic retinopathy in addition to having a hypoglycemic effect." | 5.05 | Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. ( Baba, S; Fukui, I; Goto, Y; Maezawa, H; Nakagawa, S; Sakamoto, N; Takebe, K; Takeda, R, 1983) |
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia." | 4.91 | Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015) |
"Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk." | 4.91 | Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. ( Chan, SP; Colagiuri, S, 2015) |
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs." | 4.90 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014) |
" The onset of his hypoglycemia occurred within days after starting voriconazole and subsequently fluconazole for a fungal pneumonia." | 3.88 | Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report. ( Austin, E; Gunaratne, K; Wu, PE, 2018) |
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone." | 3.83 | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
" Dosage of metformin was maintained throughout the study, and the sulfonylurea was stopped." | 3.82 | Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. ( Chang, CC; Chuang, LM; Jiang, YD; Lu, CH; Wang, CY; Wu, HP, 2006) |
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
"The risk for hypoglycemia when taking glyburide compared with modified-release gliclazide remains to be established in older adults in routine care." | 3.81 | The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. ( Clemens, KK; Dixon, SN; Fleet, JL; Garg, AX; Hramiak, I; McArthur, E, 2015) |
"We conducted a population-based cohort study of patients aged 66 years and older who were hospitalized for acute myocardial infarction or who underwent percutaneous coronary intervention between 1 April 2007 and 31 March 2010 while receiving either glyburide or gliclazide." | 3.78 | Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. ( Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR, 2012) |
"To report a case of exposure to gliclazide and ramipril during pregnancy in a patient with diabetes mellitus and hypertension." | 3.75 | Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy. ( Akar, M; Kolagasi, O; Sari, F; Sari, R, 2009) |
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide." | 3.74 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007) |
"The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone." | 3.68 | Gliclazide in the treatment of obese non-insulin dependent diabetic patients. ( Seshiah, V; Suresh, K; Venkataraman, S, 1993) |
"A long-term follow-up study was carried out in 44 Type II diabetic patients to confirm the lack of effect of gliclazide on body weight as well as its hypoglycaemic efficacy and tolerance." | 3.67 | Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. ( Lowe, SM; Robb, GH, 1984) |
"3% of ideal body weight), with an impaired daily glycaemic profile despite a carbohydrate restrictive diet were treated with gliclazide (40 to 320 mg per day) for 36 months." | 3.67 | Is sulphonylurea therapy effective long term? A 3-year study with gliclazide. ( Lavielle, R; Zurro Hernandez, J, 1986) |
"The effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated." | 3.66 | Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment. ( Abe, M; Ikeda, Y; Minami, N, 1983) |
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
"Therefore, we compared the renal hemodynamic effects of dapagliflozin with gliclazide in type 2 diabetes." | 2.94 | The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. ( Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH, 2020) |
"Patients with type 2 diabetes (T2D) are usually treated with (combinations of) glucose-lowering medication." | 2.94 | Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. ( Davids, M; Herrema, H; Kramer, MHH; Nieuwdorp, M; van Bommel, EJM; van Raalte, DH, 2020) |
"Forty-four people with type 2 diabetes were randomized to 12 weeks of dapagliflozin 10 mg/day or gliclazide 30 mg/day treatment." | 2.94 | Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. ( Heerspink, HJL; Joles, JA; Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Ruiter, D; Smits, MM; Touw, DJ; van Bommel, EJM; van Raalte, DH, 2020) |
"Eighty patients with type 2 diabetes and HbA1c between 7." | 2.90 | Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. ( Greco, EL; Greco, G; Negro, R, 2019) |
" The incidences of adverse events (AEs) were 29." | 2.84 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. ( Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D, 2017) |
"0%) with a stable dosage of metformin plus gliclazide for more than 3 months were randomized to receive either vildagliptin 50 mg twice daily (BID, n = 37) or saxagliptin 5 mg once daily (QD, n = 36)." | 2.82 | Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. ( Jing, W; Shunyou, D; Xiaochun, H; Xiaoyan, C; Yingyu, F; Yuyu, T, 2016) |
"We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial." | 2.82 | Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016) |
"Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents attained greater benefit from once-daily insulin glargine plus gliclazide modified release regimen than from a twice-daily premixed insulin regimen." | 2.80 | Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. ( Guo, L; Guo, X; Jia, W; Li, Q; Mo, Y; Tian, H; Yang, H; Zhang, M; Zheng, F; Zhou, J, 2015) |
"A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1." | 2.79 | Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. ( Arima, H; Chalmers, J; Harrap, S; Hirakawa, Y; Mancia, G; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
"In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality." | 2.79 | The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
"One hundred and one patients with type 2 diabetes who failed to achieve HbA1c<7% on previous metformin monotherapy were included to the study." | 2.77 | KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. ( Babjakova, E; Fabianova, M; Javorsky, M; Klimcakova, L; Kozarova, M; Salagovic, J; Schroner, Z; Tkac, I; Tkacova, R; Zidzik, J, 2012) |
"A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide." | 2.76 | Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. ( Bu, P; Lei, MX; Liao, EY; Luo, J; Mo, ZH; Xie, YH; Zhang, H, 2011) |
"Twenty men with type 2 diabetes (aged 50-70 years) treated with diet, metformin or sulfonylurea alone were recruited from North Glasgow University National Health Service Trusts' diabetes clinics and randomised to either metformin or gliclazide for 10 weeks." | 2.76 | AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. ( Boyle, JG; Cleland, SJ; Connell, JM; Jones, GC; Logan, PJ; Salt, IP; Sattar, N; Small, M, 2011) |
"Type 2 diabetes has been associated with an increased risk of cancer." | 2.76 | Intensive glucose control and risk of cancer in patients with type 2 diabetes. ( Chalmers, J; De Bruin, ML; Grobbee, DE; Kengne, AP; Knol, MJ; Leufkens, HG; Patel, A; Stefansdottir, G; Woodward, M; Zoungas, S, 2011) |
" The overall incidence of any adverse events was similar in both groups (approximately 61%), but the number of serious adverse events was higher in the gliclazide group (8." | 2.75 | A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. ( Filozof, C; Gautier, JF, 2010) |
"Ninety-eight patients with type 2 diabetes and a fasting blood glucose (FBG) levels between 7." | 2.75 | Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. ( Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M, 2010) |
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes." | 2.75 | Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010) |
"In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events." | 2.75 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010) |
"Male and female patients with Type 2 diabetes inadequately managed with metformin or sulfonylurea." | 2.74 | Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. ( Brazzale, AR; Mariz, S; Pacini, G; Roden, M, 2009) |
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain." | 2.73 | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008) |
" However, glibenclamide, regardless of the dosage schedule, tends to lower the plasma glucose values between midnight and early morning." | 2.73 | Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients. ( Futami-Suda, S; Kigawa, Y; Nakano, H; Norose, J; Oba, K; Ouchi, M; Suzuki, K; Suzuki, T; Watanabe, K; Yasuoka, H, 2008) |
"About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks." | 2.73 | Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. ( Kuang, H; Liu, X; Xing, H; Yi, R; Zhang, H, 2007) |
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain." | 2.73 | Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. ( Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007) |
"Gliclazide is an SU agent believed to be more protective." | 2.73 | 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas. ( Bilinska, M; Korzeniowska-Kubacka, I; Piotrowicz, R; Potocka, J, 2007) |
"In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c." | 2.73 | The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). ( Azizi, F; Barnett, AH; Embong, M; Imamoglu, S; Krentz, AJ; Perusicová, J; Sieradzki, J; Strojek, K; Uliciansky, V; Winkler, G, 2008) |
"Gliclazide has been shown to possess free radical scavenging properties." | 2.72 | Association of gliclazide and left ventricular mass in type 2 diabetic patients. ( Chang, NC; Huang, CL; Lee, TM; Lin, MS; Pan, NH, 2006) |
"Gliclazide MR treatment produced significant reductions in fasting plasma glucose (from 7." | 2.72 | Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. ( Drzewoski, J; Zurawska-Klis, M, 2006) |
" In responders, the initial dose (30 mg) of the gliclazide MR dosing regimen induced half of the maximum hypoglycaemic effect." | 2.71 | Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. ( Francillard, M; Frey, N; Holford, NH; Jochemsen, R; Laveille, C; Paraire, M, 2003) |
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status." | 2.71 | Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003) |
"To compare the metabolic and vascular effects of two sulphonylureas (SU), gliclazide (specific for the pancreatic [SUR1] receptor) and glimepiride (a nonspecific agent that also binds to vascular and cardiac [SUR2] receptors), during chronic administration in metformin-treated patients with Type 2 diabetes (T2DM)." | 2.71 | Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. ( Davis, KR; Dhindsa, P; Donnelly, R, 2003) |
"Patients with type 2 diabetes who are inadequately controlled on a half-maximal dose of a sulphonylurea may be managed by either increasing the dose of sulphonylurea or adding another agent." | 2.71 | Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. ( Baksi, A; James, RE; Nolan, JJ; Zhou, B, 2004) |
"159 patients with type 2 diabetes were parallelly assigned to a slow-released-gliclazide or gliclazide group in a randomized, open, multi-center phase III study to compare the efficacy of slow-released-gliclazide and gliclazide on overall diabetes control through HbA1c and the adverse events including hypoglycemic episodes and change of vital signs, electrocardiogram and clinical laboratory parameters after a 12-week treatment period." | 2.71 | [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus]. ( Gao, Y; Guo, XH; Li, GW; Li, HB; Pan, CY; Tian, H; Xing, XY; Yang, WY; Yuan, SY, 2004) |
"An open-label prospective cross-over trial was performed to compare the efficacy and safety of once daily low-dose gliclazide (20 mg/day) with that of nateglinide at the usual dosage (270 mg/day, 90 mg t." | 2.71 | Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. ( Kawamori, R; Miwa, S; Ohmura, C; Tanaka, Y; Watada, H, 2004) |
"Gliclazide is a sulfonylurea compound oral hypoglycemic drug that has a unique feature of restoring the first-phase insulin secretion, which is lost in T2DM being one of the early features of disease." | 2.71 | NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR. ( Brădescu, OM; Gavrilă, L; Guja, C; Ionescu-Tîrgovişte, C, 2004) |
"Repaglinide has minimal physiological advantage over gliclazide, but both therapies for type 2 diabetes fall far short of correcting the endocrine and metabolic abnormalities." | 2.71 | Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. ( Caumo, A; Cobelli, C; Singhal, P; Taylor, R, 2005) |
"Metformin is a well-known oral hypoglycaemic agent and has been commonly used, in combination with sulphonylurea, to treat type 2 diabetes." | 2.71 | Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. ( Hayaishi-Okano, R; Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Ohtoshi, K; Yamasaki, Y, 2004) |
" After dosing glibenclamide induced a significant (P = 0." | 2.71 | Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients. ( Boes, U; Wascher, TC, 2005) |
"Pioglitazone monotherapy was equivalent to gliclazide in reducing HbA1c, with specific differences between treatments in terms of mechanism of action, plasma lipids and adverse events." | 2.71 | A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. ( Brunetti, P; Charbonnel, BH; Hanefeld, M; Matthews, DR; Schernthaner, G, 2005) |
"Metformin treatment showed either small mean increases or decreases." | 2.71 | Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. ( Belcher, G; Schernthaner, G, 2005) |
" The objective of the DIACOM (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes) study was to compare the compliance of patients treated with once-daily (od) or twice-daily (bid) sulphonylureas." | 2.71 | The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). ( Kardas, P, 2005) |
"In conclusion, in long-standing type 2 diabetes the acute administration of gliclazide significantly enhances second phase insulin release at a moderately elevated blood glucose level." | 2.70 | Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus. ( Ligtenberg, JJ; Reitsma, WD; van Haeften, TW, 2001) |
"To this end, 10 patients with type 2 diabetes (age 53 +/- 2 years, BMI 27." | 2.70 | Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. ( Hansen , AP; Juhl, CB; Pincus, SM; Pørksen, N; Schmitz, O; Veldhuis, JD, 2001) |
"Fifty patients of uncontrolled type 2 diabetes were divided in to two groups." | 2.70 | Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study. ( Chugh, K; Chugh, SN; Dhawan, R; Kishore, K; Sharma, A, 2001) |
"Fifty-seven patients affected by type 2 diabetes for at least 5 years, aged 61." | 2.69 | [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data]. ( Arcangeli, A; Fiore, G; Galeone, F; Mannucci, E, 1998) |
"Forty patients with type 2 diabetes mellitus who were on conventional insulin therapy (subcutaneous insulin therapy consisting of regular and NPH insulin, two times a day) were included in the study." | 2.69 | Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. ( Gedik, O; Güvener, N, 1999) |
" Patients were randomly assigned to sulphonylurea increased up to its maximum dosage (1st group) or to addition of metformin (2nd group)." | 2.69 | Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. ( Ambrosi, F; Carle, F; Filipponi, P; Gregorio, F; Manfrini, S; Merante, D; Testa, R; Velussi, M, 1999) |
"Gliclazide was measured using h." | 2.69 | Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. ( Barrett, PH; Beilby, JP; Daly, F; Davis, TM; Dusci, LJ; Ilett, KF; Walsh, JP, 2000) |
"Fifty-three Chinese patients with NIDDM (mean age 53." | 2.68 | Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. ( Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW, 1995) |
" Moreover adding a bed-time dosage to the standard administration at meal times seems to be an effective therapeutical strategy." | 2.68 | Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study. ( Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Santucci, A, 1997) |
"Subjects with NIDDM have increased plasma proinsulin concentrations, compared with nondiabetic subjects, both in absolute terms and as a proportion of circulating insulin-like molecules." | 2.68 | Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. ( Barrow, BA; Levy, JC; Manley, SE; Rachman, J; Turner, RC, 1997) |
"Forty-four patients with NIDDM, already treated with a sulphonylurea, took part in an open, randomised, group comparison study of 12 weeks duration, during which they received either repaglinide or glibenclamide twice daily." | 2.67 | Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. ( Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH, 1993) |
" The dosage was adjusted to obtain adequate control or up to the maximum recommended dosage." | 2.67 | Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. ( Harrower, AD, 1991) |
"Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world." | 2.67 | Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991) |
"Gliclazide was significantly better than glipizide (p less than 0." | 2.67 | Comparison of secondary failure rate between three second generation sulphonylureas. ( Harrower, AD; Wong, C, 1990) |
"A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high." | 2.53 | Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature. ( Cao, X; Feng, X; Hu, Y; Jiang, L; Li, Q; Liu, C; Luo, Y; Ma, J; Wang, Y; Yan, R; Yang, F; Yuan, L; Zhao, E; Zhu, Y, 2016) |
"The primary aim must be the treatment of the insulin resistance." | 2.43 | [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005) |
"Pioglitazone is a TZD that provides appropriate monotherapy or combination treatment for patients with type 2 diabetes." | 2.42 | Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. ( Campbell, IW, 2004) |
"The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | 2.42 | Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
" The absorption rate of glibenclamide and tolbutamide was not affected by food." | 2.41 | [Timing of administration of sulfonyl urea derivatives]. ( de Smet, PA; Fischer, HR, 2000) |
" Employing an innovative pharmaceutical form based on a hydrophilic matrix to deliver this short-acting sulfonylurea, gliclazide modified release is associated with an unsurpassed efficacy:acceptability ratio, with the potential additional advantages inherent in reduced dosage and once-daily administration." | 2.41 | Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. ( Harrower, A, 2000) |
"Gliclazide MR has also demonstrated antioxidant properties that are independent of glycaemic control." | 2.41 | Gliclazide modified release. ( Goa, KL; McGavin, JK; Perry, CM, 2002) |
"Gliclazide is a second-generation sulfonylures that is widely used in the treatment of non-insulin-dependent diabetes mellitus (Type 2 diabetes)." | 2.39 | [Gliclazide: review of metabolic and vascular action]. ( Alberti, KG, 1994) |
"Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)." | 2.38 | Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. ( Brogden, RN; Palmer, KJ, 1993) |
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)." | 2.38 | Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992) |
"Many NIDDM patients exhibit poor compliance with regard to exercise and diet, and require oral hypoglycemics." | 2.38 | The treatment of NIDDM in the decade of the 90s. ( Krall, LP, 1991) |
"Gliclazide is a sulphonylurea drug with an intermediate half-life of around 11 hours." | 2.38 | The mode of action and clinical pharmacology of gliclazide: a review. ( Campbell, DB; Lavielle, R; Nathan, C, 1991) |
"Treatment with gliclazide of patients with NIDDM has been shown to be associated with a potentiation of both insulin-mediated glucose disposal and insulin-stimulated glycogen synthase activity in skeletal muscle." | 2.38 | Gliclazide and insulin action in human muscle. ( Bak, JF; Pedersen, O, 1991) |
"Gliclazide is a second-generation sulfonylurea drug whose efficacy in the treatment of NIDDM, alone or in combination with insulin, has been widely demonstrated." | 2.38 | Current status of non-insulin-dependent diabetes mellitus (type II): management with gliclazide. ( Rifkin, H, 1991) |
"Gliclazide was approved as a treatment for type 2 diabetes in an era before model-based drug development, and consequently, the recommended doses were not optimised with modern methods." | 1.91 | Optimal dosing of gliclazide-A model-based approach. ( Cotton, MF; Hussein, H; Karamchand, S; Kjellsson, MC; Leisegang, R; Mim, SR; Naidoo, P; Rambiritch, V; Vidadi, S, 2023) |
"A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study)." | 1.72 | Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. ( Chalmers, J; Hamet, P; Harrap, S; Harris, K; Mancia, G; Poulter, N; Rodgers, A; Wang, N; Williams, B; Woodward, M; Zoungas, S, 2022) |
"Non-alcoholic fatty liver disease (NAFLD) was evaluated by abdominal ultrasound, and fibrosis stages were evaluated at baseline and 8 months." | 1.72 | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. ( Fu, BY; Wang, XJ, 2022) |
" The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide." | 1.51 | Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model. ( Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019) |
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
"To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with metformin and/or gliclazide." | 1.48 | Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. ( Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018) |
" It is dosed in modified release tablets." | 1.48 | Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients. ( Czyrski, A; Hermann, T; Resztak, M, 2018) |
"Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients." | 1.46 | Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. ( Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D, 2017) |
"Vildagliptin is a new drug used to treat diabetes mellitus (DM)." | 1.46 | A case of bullous pemphigoid ınduced by vildagliptin. ( Ersoy-Evans, S; Gököz, O; Gönül, M; Keseroglu, HO; Taş-Aygar, G, 2017) |
"The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)." | 1.43 | Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016) |
"A total of 746 incident type 2 diabetes patients were included in this study." | 1.43 | CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. ( Chen, D; Chen, P; Guo, Y; Han, C; Liu, Z; Zeng, W, 2016) |
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes." | 1.43 | Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016) |
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae." | 1.42 | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015) |
"In primary care, once daily, breakable extended release gliclazide XR 60 mg, with a simple two step titration to administer maximum recommended dosage is effective in achieving short term glycemic control with a low frequency of hypoglycaemia, in monotherapy or in combination with metformin." | 1.42 | Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study. ( Chopra, V; Jain, S; Jayaprakashsai, J; Mohan, V; Sanyal, D, 2015) |
"Gliclazide or metformin-treated patients demonstrated lesser mortality risk than glibenclamide-treated ones in all four evaluation models, but age and duration stratification can influence this phenomenon in case of "first prescription model"." | 1.40 | Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. ( Khalangot, M; Kovtun, V, 2014) |
"Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
"Often misdiagnosed as type 1 or type 2 diabetes, maturity-onset diabetes of the young (MODY) is the most common form of monogenic diabetes, accounting for 1-2% of all diabetes cases." | 1.37 | Diagnosis in diabetes: does it matter? ( Robertson, L; Swaminathan, K; Thethy, I, 2011) |
" Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium." | 1.36 | [Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
"Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties." | 1.36 | Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. ( Chan, JC; Chow, CC; Ko, GT; Kong, AP; Luk, AO; Ma, RC; Ng, VW; Ozaki, R; So, WY; Tong, PC; Yang, X; Yu, LW, 2010) |
"The study objective was to determine if Ramadan fasting was safe in patients with type 2 diabetes mellitus (T2D), based upon a determination of the effect of fasting on a broad range of physiological and clinical parameters, including markers of glycemic control and blood pressure." | 1.35 | Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control? ( Chabraoui, L; Chebraoui, L; Chraibi, A; El Guessabi, L; Fellat, S; Israili, ZH; Lyoussi, B; M'guil, M; Ragala, MA, 2008) |
" Subsequently, the effects of a 1-week chronic daily dosing of DPP-IV inhibitors and sulfonylureas were investigated." | 1.35 | Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. ( Hayakawa, M; Matsuyama-Yokono, A; Nakano, R; Shibasaki, M; Shiraki, K; Someya, Y; Tahara, A, 2009) |
"gliclazide treatment." | 1.35 | Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009) |
"Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring." | 1.35 | Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009) |
"Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease." | 1.35 | In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). ( Blasiak, J; Drzewoski, J; Kasznicki, J; Sliwinska, A, 2008) |
"A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia." | 1.34 | Insulinoma causing hypoglycemia in a patient with type 2 diabetes. ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007) |
"Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | 1.33 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
"Gliclazide is an oral hypoglycemic agent that belongs to the class of sulfonylureas: basic and clinical evidences suggest that gliclazide works as an antioxidative drug, independently from its ability to reduce hyperglycemia." | 1.33 | Effects of gliclazide beyond metabolic control. ( Ceriello, A, 2006) |
"Adult patients with type 2 diabetes controlled with insulin frequently require the addition of insulin sensitising drugs such as metformin and sometimes glitazones to achieve optimum glycaemic control." | 1.33 | Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin. ( Brown, N, 2006) |
"Insulin resistance is a key feature of type 2 diabetes mellitus." | 1.32 | Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide. ( Antić, S; Bogicević, M; Milojković, M; Mitić-Zlatković, M; Stefanović, V; Stojiljković, S; Vlahović, P, 2003) |
"8%, and increase in percentage of once-daily dosing regimen from 12 to 58." | 1.32 | [Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]. ( Guillausseau, PJ, 2004) |
"Weight reduction was observed in all the treatment groups." | 1.32 | [Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?]. ( Stalder, Dde M, 2004) |
"The subjects were 55 patients with type 2 diabetes." | 1.31 | Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. ( Kubo, K, 2002) |
" All patients were stable, with no change in dosage for at least 3 months." | 1.30 | Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination. ( Guillausseau, PJ, 1997) |
"In gliclazide-treated NIDDM patients, PDH activity in circulating lymphocytes recovered." | 1.30 | Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus. ( Bruno, R; Curto, M; Gamba, S; Mioletti, S; Mostert, M; Piccinini, M; Rabbone, I; Rinaudo, MT, 1998) |
"Gliclazide treatment lowered LPS-stimulated TNF-alpha production by diabetic monocytes to levels similar to those observed in control subjects." | 1.30 | Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. ( Desfaits, AC; Renier, G; Serri, O, 1998) |
"Gliclazide-treated Goto-Kakisaki rats were evaluated against Wistar and untreated Goto-Kakisaki rats." | 1.30 | Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats. ( Bailbé, D; Dachicourt, N; Gangnerau, MN; Portha, B; Ravel, D; Serradas, P, 1998) |
"The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops." | 1.30 | Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998) |
"Gliclazide treatment results in increased serum C-peptide, decreased hemoglobin-A1c, decreased glucose excursion on glucose tolerance test, and 35% increased insulin-stimulated glucose disposal." | 1.29 | Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study. ( Bjørbaek, C; Hansen, L; Kahn, BB; Pedersen, O; Rosen, AS; Vestergaard, H; Weinreb, JE, 1995) |
"Gliclazide was applied in the group I (11 patients, mean age 63." | 1.29 | [Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?]. ( Bresler, M; Grzeszczak, W; Gumprecht, J; Strojek, K; Trautsolt, W, 1993) |
"Five male non-obese newly diagnosed NIDDM and 5 age-, sex- and body mass index (BMI) matched healthy controls without a family history of diabetes were submitted to a frequently sampled intravenous (i." | 1.29 | Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM). ( Porrelli, RN; Santomauro, AT; Wajchenberg, BL, 1993) |
"Gliclazide treatment was associated with significant reductions in HbA1C (p=0." | 1.29 | Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control. ( Bjørbaek, C; Lund, S; Pedersen, O; Vestergaard, H, 1995) |
" Thus the insulinogenic effect of gliclazide could be masked during long-term administration by a concomitant effect of gliclazide which increases hepatic extraction of insulin." | 1.28 | Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus. ( Borghi, VC; Giannella-Neto, D; Porrelli, RN; Santomauro, AT; Wajchenberg, BL, 1992) |
"Gliclazide was given to group A following CSII and to 5 obese NIDDM patients (group B) in their habitual hyperglycemic state." | 1.28 | Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991) |
" Adverse effects were reported by 22 patients, including dizziness and light-headedness, diarrhea, nausea, palpitations and pruritus, but none required modification of Diamicron therapy." | 1.28 | Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. ( Dudley, J; Kalb, B; Kilo, C, 1991) |
"Gliclazide was given to group A following CSII, and to five obese NIDDM patients (group B) in their habitual hyperglycemic state." | 1.28 | Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. ( Cerasi, E; del Rio, G; Della Casa, L; Glaser, B, 1991) |
"Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether." | 1.28 | The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels. ( Batch, J; Bird, D; Cameron, D; Charles, B; Ma, A; Noble, R; Ravenscroft, P, 1990) |
" Gliclazide taken 30 minutes before breakfast increased in serum concentration before the meal-induced hyperglycemia, but that taken just before or just after breakfast was poorly absorbed and showed smaller and greatly delayed peaks." | 1.28 | The effect of timing on gliclazide absorption and action. ( Ishibashi, F; Takashina, S, 1990) |
"Gliclazide treatment was associated with improved glycemic control and enhanced pancreatic beta-cell responses to meal stimulation." | 1.28 | Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. ( Bak, JF; Pedersen, O; Schmitz, O; Sørensen, NS, 1989) |
"Gliclazide (80 mg bd) was administered to nine subjects with type 2 (non insulin dependent) diabetes inadequately controlled on diet only." | 1.28 | The effects of long term gliclazide administration on insulin secretion and insulin sensitivity. ( Bird, D; Cameron, DP; Howlett, V; Kamp, M; Ma, A, 1989) |
"Mean body weight was reduced, particularly in obese and elderly subjects and those treated previously with sulphonylurea drugs." | 1.27 | Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. ( Campbell, DB; Shaw, KM; Ward, JD; Wheeley, MS, 1985) |
"Gliclazide is a suitable oral hypoglycaemic agent for use in the obese diabetic who cannot be controlled by diet alone." | 1.27 | A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. ( Frier, BM; Kay, JW; McAlpine, CH; McAlpine, LG; Storer, AM; Waclawski, ER, 1988) |
"Gliclazide was proven to be a reliable blood-sugar lowering agent with a generally good subjective tolerance." | 1.27 | [Gliclazide in the non-insulin-dependent diabetic patient in geriatrics]. ( Böhmer, F; Frühwald, T, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 42 (10.55) | 18.7374 |
1990's | 90 (22.61) | 18.2507 |
2000's | 125 (31.41) | 29.6817 |
2010's | 111 (27.89) | 24.3611 |
2020's | 30 (7.54) | 2.80 |
Authors | Studies |
---|---|
Kumar, A | 1 |
Maurya, RA | 1 |
Sharma, S | 2 |
Ahmad, P | 1 |
Singh, AB | 1 |
Tamrakar, AK | 1 |
Srivastava, AK | 1 |
Raza, SA | 1 |
Akram, J | 1 |
Aamir, AH | 1 |
Ahmedani, Y | 1 |
Hassan, MI | 1 |
Soelistijo, SA | 1 |
Aman, AM | 1 |
Zufry, H | 1 |
Pranoto, A | 1 |
Rudijanto, A | 1 |
Hassanien, M | 1 |
Bajaj, HS | 1 |
Chu, L | 1 |
Bansal, N | 1 |
Brown, RE | 1 |
Dhillon, G | 1 |
Gupta, R | 1 |
Bhela, JS | 1 |
Padda, JK | 1 |
Khandwala, H | 1 |
Venn, K | 1 |
Aronson, R | 1 |
Ohkuma, T | 3 |
Harris, K | 2 |
Cooper, M | 7 |
Grobbee, DE | 7 |
Hamet, P | 14 |
Harrap, S | 17 |
Mancia, G | 15 |
Marre, M | 15 |
Patel, A | 16 |
Rodgers, A | 6 |
Williams, B | 12 |
Woodward, M | 25 |
Chalmers, J | 28 |
Wang, N | 1 |
Poulter, N | 17 |
Zoungas, S | 21 |
Tomlinson, B | 1 |
Li, YH | 1 |
Chan, P | 1 |
Solanki, R | 1 |
Wadhwana, P | 1 |
Patel, R | 1 |
Gayakvad, B | 1 |
Kothari, C | 1 |
Patel, C | 1 |
Mim, SR | 1 |
Hussein, H | 1 |
Vidadi, S | 1 |
Leisegang, R | 1 |
Karamchand, S | 1 |
Rambiritch, V | 2 |
Cotton, MF | 1 |
Naidoo, P | 2 |
Kjellsson, MC | 1 |
Paz-Pacheco, E | 1 |
Nevado, J | 1 |
Paz, EMC | 1 |
Jasul, G | 1 |
Aman, AYC | 1 |
Alejandro-Ribaya, EL | 1 |
Francisco, MD | 1 |
Guanzon, MLV | 1 |
Uyking-Naranjo, M | 1 |
Añonuevo-Cruz, C | 1 |
Maningat, MPD | 1 |
Jaring, C | 1 |
Nacpil-Dominguez, P | 1 |
Pala-Mohamad, A | 1 |
Uy-Canto, A | 1 |
Quisumbing, JP | 1 |
Lat, AM | 1 |
Bernardo, DC | 1 |
Mansibang, NM | 1 |
Ribaya, VS | 1 |
Calpito, KJA | 1 |
Ferrer, JP | 1 |
Biwang, J | 1 |
Melegrito, J | 1 |
Deguit, CD | 1 |
Panerio, CE | 1 |
Lim, LL | 1 |
S H Lau, E | 1 |
Pheng Chan, S | 1 |
Ji, L | 2 |
Lim, S | 1 |
Sirinvaravong, S | 1 |
Unnikrishnan, AG | 1 |
O Y Luk, A | 1 |
Cortese, V | 2 |
Durocher, A | 1 |
C N Chan, J | 1 |
Kalra, S | 2 |
Lee, AK | 1 |
Wang, D | 2 |
Warren, B | 1 |
Sharrett, AR | 1 |
Mcevoy, JW | 2 |
Selvin, E | 2 |
Ungurianu, A | 1 |
Şeremet, O | 1 |
Gagniuc, E | 1 |
Olaru, OT | 1 |
Guţu, C | 1 |
Grǎdinaru, D | 1 |
Ionescu-Tȋrgovişte, C | 2 |
Marginǎ, D | 1 |
Dǎnciulescu-Miulescu, R | 1 |
Vianna, AGD | 2 |
Lacerda, CS | 2 |
Pechmann, LM | 2 |
Polesel, MG | 2 |
Marino, EC | 2 |
Scharf, M | 1 |
Detsch, JM | 1 |
Marques, K | 1 |
Sanches, CP | 1 |
Panda, BP | 1 |
Krishnamoorthy, R | 1 |
Bhattamisra, SK | 1 |
Shivashekaregowda, NKH | 1 |
Seng, LB | 1 |
Patnaik, S | 1 |
van Bommel, EJM | 4 |
Muskiet, MHA | 3 |
van Baar, MJB | 1 |
Tonneijck, L | 1 |
Smits, MM | 2 |
Emanuel, AL | 1 |
Bozovic, A | 1 |
Danser, AHJ | 2 |
Geurts, F | 2 |
Hoorn, EJ | 2 |
Touw, DJ | 3 |
Larsen, EL | 1 |
Poulsen, HE | 1 |
Kramer, MHH | 4 |
Nieuwdorp, M | 4 |
Joles, JA | 3 |
van Raalte, DH | 4 |
Mifsud, S | 1 |
Schembri, EL | 1 |
Fava, S | 1 |
Herrema, H | 1 |
Davids, M | 1 |
Mathavan, S | 1 |
Ionescu, CM | 1 |
Kovacevic, B | 1 |
Mikov, M | 1 |
Golocorbin-Kon, S | 1 |
Mooranian, A | 1 |
Dass, CR | 1 |
Al-Salami, H | 1 |
Tian, J | 1 |
Wang, JG | 1 |
Ruiter, D | 1 |
Heerspink, HJL | 1 |
Saberi, M | 1 |
Ramazani, Z | 1 |
Rashidi, H | 1 |
Saberi, A | 1 |
Cho, EH | 1 |
Han, K | 1 |
Kim, B | 1 |
Lee, DH | 1 |
Zaccardi, F | 1 |
Jacquot, E | 1 |
Tyrer, F | 1 |
Seidu, S | 1 |
Davies, MJ | 2 |
Khunti, K | 1 |
Gao, S | 1 |
Chen, Y | 2 |
Hu, R | 1 |
Lu, W | 1 |
Yu, L | 1 |
Chen, J | 1 |
Liu, S | 1 |
Guo, Y | 2 |
Shen, Q | 1 |
Wang, B | 1 |
Fang, W | 1 |
Lee, KF | 1 |
Mak, MWH | 1 |
Lao, VWN | 1 |
Yip, HLK | 1 |
Lau, WY | 1 |
Wong, VTL | 1 |
Post, A | 1 |
Bakker, SJL | 1 |
van Berkel, M | 1 |
Ferrannini, E | 1 |
Morieri, ML | 1 |
Vitturi, N | 1 |
Avogaro, A | 3 |
Targher, G | 1 |
Fadini, GP | 2 |
Cordiner, RLM | 2 |
Mari, A | 1 |
Tura, A | 1 |
Pearson, ER | 3 |
Fu, BY | 1 |
Wang, XJ | 1 |
Huang, X | 1 |
Zhou, Y | 2 |
Tang, H | 1 |
Liu, B | 1 |
Su, B | 1 |
Wang, Q | 1 |
Quarella, M | 1 |
Walser, D | 1 |
Brändle, M | 1 |
Fournier, JY | 1 |
Bilz, S | 1 |
Feng, W | 1 |
Gao, C | 1 |
Bi, Y | 3 |
Wu, M | 1 |
Li, P | 2 |
Shen, S | 1 |
Chen, W | 1 |
Yin, T | 1 |
Zhu, D | 2 |
Mohammedi, K | 3 |
Colagiuri, S | 5 |
Das, AK | 1 |
Douros, A | 1 |
Yin, H | 1 |
Yu, OHY | 1 |
Filion, KB | 1 |
Azoulay, L | 1 |
Suissa, S | 1 |
van Steen, SC | 1 |
Li, Q | 13 |
Cooper, ME | 4 |
DeVries, JH | 1 |
Hu, C | 2 |
Zhao, X | 1 |
Luo, P | 1 |
Lu, J | 2 |
Chen, M | 2 |
Yan, D | 1 |
Lu, X | 1 |
Kong, H | 1 |
Jia, W | 3 |
Xu, G | 1 |
Zatti, G | 1 |
Baldi, I | 1 |
Bottigliengo, D | 1 |
Consoli, A | 1 |
Giaccari, A | 1 |
Sesti, G | 2 |
Heald, AH | 1 |
Livingston, M | 1 |
Bien, Z | 1 |
Moreno, GYC | 1 |
Laing, I | 1 |
Stedman, M | 1 |
Cozzani, E | 1 |
Di Zenzo, G | 1 |
Cioni, M | 1 |
Javor, S | 1 |
Altieri, M | 1 |
Anselmi, L | 1 |
Parodi, A | 1 |
Negro, R | 1 |
Greco, EL | 1 |
Greco, G | 1 |
Faria-Neto, JR | 1 |
Gunaratne, K | 1 |
Austin, E | 1 |
Wu, PE | 1 |
Matthews, D | 2 |
Leiter, LA | 2 |
Chan, SP | 2 |
Garcia de Lucas, MD | 1 |
Pérez Belmonte, LM | 1 |
Suárez Tembra, M | 1 |
Olalla Sierra, J | 1 |
Gómez Huelgas, R | 1 |
Feng, WH | 1 |
Yin, TT | 1 |
Gao, CX | 1 |
Shen, SM | 1 |
Gao, LJ | 1 |
Yang, DH | 2 |
Zhu, DL | 1 |
Challier, C | 1 |
Laurella, S | 1 |
Allegretti, P | 1 |
Sabini, C | 1 |
Sabini, L | 1 |
García, NA | 1 |
Biasutti, A | 1 |
Criado, S | 1 |
Czyrski, A | 1 |
Resztak, M | 1 |
Hermann, T | 1 |
Juraschek, SP | 1 |
Lazo, M | 1 |
Huang, HK | 1 |
Yeh, JI | 1 |
Lee, JY | 1 |
Jang, SY | 1 |
Nam, CM | 1 |
Kang, ES | 2 |
Sekeroglu, MA | 1 |
Taylan Sekeroglu, H | 1 |
Bo, S | 1 |
Castiglione, A | 1 |
Ghigo, E | 1 |
Gentile, L | 1 |
Durazzo, M | 1 |
Cavallo-Perin, P | 1 |
Ciccone, G | 1 |
Abdelmoneim, AS | 4 |
Eurich, DT | 2 |
Gamble, JM | 1 |
Johnson, JA | 1 |
Seubert, JM | 2 |
Qiu, W | 3 |
Simpson, SH | 4 |
Konig, M | 1 |
Lamos, EM | 1 |
Stein, SA | 1 |
Davis, SN | 1 |
Pu, R | 1 |
Geng, XN | 1 |
Yu, F | 3 |
Liang, HG | 1 |
Shi, LW | 1 |
Contreras-Steyls, M | 1 |
Vílchez-Márquez, F | 1 |
Mota, A | 1 |
Moyano, B | 1 |
Herrera-Ceballos, E | 1 |
Arima, H | 3 |
Hirakawa, Y | 5 |
Yamout, H | 1 |
Bakris, GL | 1 |
Landman, GW | 2 |
de Bock, GH | 1 |
van Hateren, KJ | 2 |
van Dijk, PR | 1 |
Groenier, KH | 2 |
Gans, RO | 1 |
Houweling, ST | 1 |
Bilo, HJ | 1 |
Kleefstra, N | 2 |
Blomster, JI | 1 |
Chow, CK | 1 |
Neal, B | 11 |
Hillis, GS | 1 |
Pareek, A | 1 |
Chandurkar, N | 1 |
Thomas, N | 1 |
Viswanathan, V | 1 |
Deshpande, A | 1 |
Gupta, OP | 1 |
Shah, A | 1 |
Kakrani, A | 1 |
Bhandari, S | 1 |
Thulasidharan, NK | 1 |
Saboo, B | 1 |
Devaramani, S | 1 |
Vijaykumar, NB | 1 |
Agrawal, N | 1 |
Mahesh, M | 1 |
Kothari, K | 1 |
Erem, C | 1 |
Ozbas, HM | 1 |
Nuhoglu, I | 1 |
Deger, O | 1 |
Civan, N | 1 |
Ersoz, HO | 1 |
Ninomiya, T | 3 |
Hassanein, M | 3 |
Abdallah, K | 1 |
Schweizer, A | 1 |
Zhao, F | 1 |
Ma, YF | 1 |
Wen, JX | 1 |
DU, YF | 1 |
Li, CL | 1 |
Li, GW | 3 |
Billot, L | 4 |
Monaghan, H | 1 |
Joshi, R | 4 |
Glasziou, P | 4 |
Grobbee, D | 3 |
Heller, S | 7 |
Lisheng, L | 4 |
Matthews, DR | 8 |
Mogensen, CE | 2 |
Perkovic, V | 5 |
MacMahon, S | 7 |
van der Leeuw, J | 2 |
Visseren, FL | 2 |
Kengne, AP | 6 |
van der Graaf, Y | 2 |
Khalangot, M | 2 |
Kovtun, V | 2 |
Mogensen, UM | 1 |
Andersson, C | 1 |
Fosbøl, EL | 1 |
Schramm, TK | 1 |
Vaag, A | 1 |
Scheller, NM | 1 |
Torp-Pedersen, C | 1 |
Gislason, G | 1 |
Køber, L | 1 |
Huang, Y | 1 |
Light, P | 1 |
Lee, YH | 1 |
Lee, CJ | 1 |
Lee, HS | 1 |
Choe, EY | 1 |
Lee, BW | 1 |
Ahn, CW | 1 |
Cha, BS | 1 |
Lee, HC | 1 |
Balkau, B | 1 |
Winkler, G | 2 |
Clemens, KK | 1 |
McArthur, E | 1 |
Dixon, SN | 1 |
Fleet, JL | 1 |
Hramiak, I | 1 |
Garg, AX | 1 |
Zhou, J | 1 |
Zheng, F | 1 |
Guo, X | 1 |
Yang, H | 1 |
Zhang, M | 1 |
Tian, H | 3 |
Guo, L | 1 |
Mo, Y | 1 |
Mbanya, JC | 1 |
Al-Sifri, S | 1 |
Abdel-Rahim, A | 1 |
Satman, I | 3 |
Hassan, MH | 1 |
Abd-Allah, GM | 1 |
Oei, E | 1 |
Samad, N | 1 |
Visser, A | 1 |
Chowdhury, TA | 2 |
Fan, SL | 1 |
Shestakova, MV | 1 |
Trubitsyna, NP | 1 |
Piletič, M | 1 |
Grobbee, R | 1 |
Jardine, M | 1 |
Singh, AK | 2 |
Singh, R | 1 |
Xiaoyan, C | 1 |
Jing, W | 1 |
Xiaochun, H | 1 |
Yuyu, T | 1 |
Shunyou, D | 1 |
Yingyu, F | 1 |
García Díaz, E | 1 |
Guagnozzi, D | 1 |
Gutiérrez, V | 1 |
Mendoza, C | 1 |
Maza, C | 1 |
Larrañaga, Y | 1 |
Perdomo, D | 1 |
Godoy, T | 1 |
Taleb, G | 1 |
Wong, MG | 1 |
Senthilselvan, A | 1 |
Zeng, W | 1 |
Chen, P | 1 |
Liu, Z | 1 |
Chen, D | 1 |
Han, C | 1 |
Juszczak, A | 1 |
Pryse, R | 1 |
Schuman, A | 1 |
Owen, KR | 1 |
Anderson, AJ | 1 |
Andrew, R | 1 |
Homer, NZ | 1 |
Jones, GC | 2 |
Smith, K | 1 |
Livingstone, DE | 1 |
Walker, BR | 1 |
Stimson, RH | 1 |
Keseroglu, HO | 1 |
Taş-Aygar, G | 1 |
Gönül, M | 1 |
Gököz, O | 1 |
Ersoy-Evans, S | 1 |
Alam, F | 1 |
Islam, MA | 1 |
Kamal, MA | 1 |
Gan, SH | 1 |
van Dijk, P | 1 |
Bouma, A | 1 |
Bilo, H | 1 |
Mohan, V | 1 |
Chopra, V | 1 |
Sanyal, D | 1 |
Jain, S | 1 |
Jayaprakashsai, J | 1 |
Tang, TT | 1 |
Jiang, F | 1 |
Zhang, R | 1 |
Yin, J | 1 |
Bao, YQ | 1 |
Cheng, X | 1 |
Jia, WP | 2 |
Feng, X | 1 |
Yuan, L | 1 |
Hu, Y | 1 |
Zhu, Y | 1 |
Yang, F | 1 |
Jiang, L | 1 |
Yan, R | 1 |
Luo, Y | 1 |
Zhao, E | 1 |
Liu, C | 1 |
Wang, Y | 1 |
Cao, X | 1 |
Ma, J | 1 |
Xu, W | 1 |
Mu, Y | 1 |
Zhao, J | 1 |
Ji, Q | 1 |
Zhou, Z | 1 |
Yao, B | 1 |
Mao, A | 1 |
Engel, SS | 1 |
Zhao, B | 1 |
Zeng, L | 1 |
Ran, X | 1 |
Yang, W | 1 |
Weng, J | 1 |
Liu, L | 2 |
Pan, C | 2 |
Bompoint, S | 1 |
de Galan, BE | 5 |
Travert, F | 3 |
Feng, Y | 2 |
Mao, G | 1 |
Ren, X | 1 |
Xing, H | 2 |
Tang, G | 1 |
Li, X | 1 |
Sun, L | 1 |
Yang, J | 1 |
Ma, W | 1 |
Wang, X | 1 |
Xu, X | 1 |
M'guil, M | 1 |
Ragala, MA | 1 |
El Guessabi, L | 1 |
Fellat, S | 1 |
Chraibi, A | 1 |
Chabraoui, L | 1 |
Chebraoui, L | 1 |
Israili, ZH | 1 |
Lyoussi, B | 1 |
Chandra, ST | 1 |
Priya, G | 1 |
Khurana, ML | 1 |
Jyotsna, VP | 1 |
Sreenivas, V | 1 |
Dwivedi, S | 1 |
Ammini, AC | 1 |
Kigawa, Y | 1 |
Oba, K | 1 |
Futami-Suda, S | 1 |
Norose, J | 1 |
Yasuoka, H | 1 |
Suzuki, K | 1 |
Ouchi, M | 1 |
Watanabe, K | 1 |
Suzuki, T | 1 |
Nakano, H | 1 |
Monami, M | 2 |
Lamanna, C | 2 |
Balzi, D | 2 |
Marchionni, N | 2 |
Mannucci, E | 5 |
Kolagasi, O | 1 |
Sari, F | 1 |
Akar, M | 1 |
Sari, R | 1 |
Matsuyama-Yokono, A | 1 |
Tahara, A | 1 |
Nakano, R | 1 |
Someya, Y | 1 |
Shiraki, K | 1 |
Hayakawa, M | 1 |
Shibasaki, M | 1 |
Walker, J | 1 |
White, R | 1 |
Vale, A | 1 |
Elliott, S | 1 |
Wass, J | 1 |
Reynolds, J | 1 |
Lumb, AN | 1 |
Gallen, IW | 1 |
Roden, M | 2 |
Mariz, S | 4 |
Brazzale, AR | 1 |
Pacini, G | 1 |
Poulter, NR | 1 |
Slim, R | 1 |
Ben Salem, C | 1 |
Zamy, M | 1 |
Zami, M | 1 |
Biour, M | 1 |
Cass, A | 1 |
Pillai, A | 3 |
Devendra, D | 1 |
Gohel, B | 1 |
Bravis, V | 1 |
Hui, E | 1 |
Salih, S | 1 |
Mehar, S | 1 |
Anderson, C | 1 |
Dufouil, C | 1 |
Hackett, M | 1 |
Heller, SR | 1 |
Pan, CY | 4 |
Foley, JE | 1 |
Sreenan, S | 1 |
Tronko, M | 1 |
Kravchenko, V | 1 |
Li, Y | 1 |
Xu, L | 1 |
Shen, J | 1 |
Ran, J | 1 |
Zhang, Y | 1 |
Wang, M | 1 |
Yan, L | 2 |
Cheng, H | 2 |
Fu, Z | 1 |
Konya, H | 1 |
Hasegawa, Y | 1 |
Hamaguchi, T | 1 |
Satani, K | 1 |
Umehara, A | 1 |
Katsuno, T | 1 |
Ishikawa, T | 1 |
Miuchi, M | 1 |
Kohri, K | 1 |
Suehiro, A | 1 |
Kakishita, E | 1 |
Miyagawa, J | 1 |
Namba, M | 1 |
Arai, K | 1 |
Matoba, K | 1 |
Hirao, K | 1 |
Matsuba, I | 1 |
Takai, M | 1 |
Takeda, H | 1 |
Kanamori, A | 1 |
Yamauchi, M | 1 |
Mori, H | 1 |
Terauchi, Y | 1 |
Wu, CZ | 1 |
Pei, D | 1 |
Hsieh, AT | 1 |
Wang, K | 1 |
Lin, JD | 2 |
Lee, LH | 1 |
Chu, YM | 1 |
Hsiao, FC | 1 |
Pei, C | 1 |
Hsia, TL | 1 |
Zargar, AH | 1 |
Siraj, M | 1 |
Jawa, AA | 1 |
Hasan, M | 1 |
Mahtab, H | 1 |
Vilar, L | 1 |
Canadas, V | 1 |
Arruda, MJ | 1 |
Arahata, C | 1 |
Agra, R | 1 |
Pontes, L | 1 |
Montenegro, L | 1 |
Vilar, CF | 1 |
Silva, LM | 1 |
Albuquerque, JL | 1 |
Gusmão, A | 1 |
Filozof, C | 1 |
Gautier, JF | 1 |
de Galan, B | 1 |
Onuchin, SG | 2 |
Elsukova, OS | 2 |
Solov'ev, OV | 2 |
Onuchina, EL | 2 |
Hu, YY | 1 |
Ye, SD | 1 |
Zhao, LL | 1 |
Zheng, M | 1 |
Wu, FZ | 1 |
Yang, X | 1 |
So, WY | 1 |
Ma, RC | 1 |
Yu, LW | 1 |
Ko, GT | 1 |
Kong, AP | 1 |
Ng, VW | 1 |
Luk, AO | 1 |
Ozaki, R | 1 |
Tong, PC | 1 |
Chow, CC | 2 |
Chan, JC | 1 |
Chen, LL | 2 |
Liao, YF | 2 |
Zeng, TS | 2 |
Li, HQ | 1 |
Kristiansen, SB | 1 |
Løfgren, B | 1 |
Nielsen, JM | 1 |
Støttrup, NB | 1 |
Buhl, ES | 1 |
Nielsen-Kudsk, JE | 1 |
Nielsen, TT | 1 |
Rungby, J | 2 |
Flyvbjerg, A | 1 |
Bøtker, HE | 1 |
Batty, GD | 1 |
Czernichow, S | 1 |
Huxley, R | 1 |
Harrap, SB | 1 |
Louro, TM | 1 |
Matafome, PN | 1 |
Nunes, EC | 1 |
da Cunha, FX | 1 |
Seiça, RM | 1 |
Zhang, H | 2 |
Bu, P | 1 |
Xie, YH | 1 |
Luo, J | 1 |
Lei, MX | 1 |
Mo, ZH | 1 |
Liao, EY | 1 |
Li, YM | 1 |
Ding, HC | 1 |
Boyle, JG | 1 |
Logan, PJ | 1 |
Small, M | 1 |
Sattar, N | 1 |
Connell, JM | 1 |
Cleland, SJ | 1 |
Salt, IP | 1 |
Stefansdottir, G | 1 |
Knol, MJ | 1 |
Leufkens, HG | 1 |
De Bruin, ML | 1 |
Hanif, W | 1 |
Malik, W | 1 |
Kamal, A | 1 |
Geransar, P | 1 |
Lister, N | 1 |
Andrews, C | 1 |
Barnett, A | 1 |
Thethy, I | 1 |
Robertson, L | 1 |
Swaminathan, K | 1 |
Matsuda, R | 1 |
Anguizola, J | 1 |
Joseph, KS | 1 |
Hage, DS | 1 |
Hasenbank, SE | 1 |
Brocks, DR | 1 |
Light, PE | 2 |
Saharan, VA | 1 |
Choudhury, PK | 1 |
Januszewicz, A | 1 |
Tandon, N | 1 |
Joshi, P | 1 |
Al-Azzam, SI | 1 |
Alomari, M | 1 |
Khader, YS | 1 |
Almahasneh, FA | 1 |
Muflih, SM | 1 |
Altawalbeh, S | 1 |
Gupta, PS | 1 |
Green, AN | 1 |
Jermendy, G | 1 |
Lang, VY | 1 |
Fatehi, M | 1 |
Javorsky, M | 1 |
Klimcakova, L | 1 |
Schroner, Z | 1 |
Zidzik, J | 1 |
Babjakova, E | 1 |
Fabianova, M | 1 |
Kozarova, M | 1 |
Tkacova, R | 1 |
Salagovic, J | 1 |
Tkac, I | 1 |
Lim, PC | 1 |
Lim, SL | 1 |
Oiyammaal, C | 1 |
Ragia, G | 1 |
Tavridou, A | 1 |
Petridis, I | 1 |
Manolopoulos, VG | 1 |
Magnusson, NE | 1 |
Dyrskjøt, L | 1 |
Grimm, D | 1 |
Wehland, M | 1 |
Pietsch, J | 1 |
Juurlink, DN | 1 |
Gomes, T | 1 |
Shah, BR | 1 |
Mamdani, MM | 1 |
Drews, G | 1 |
Düfer, M | 1 |
Kubo, K | 1 |
Fava, D | 1 |
Cassone-Faldetta, M | 1 |
Laurenti, O | 1 |
De Luca, O | 1 |
Ghiselli, A | 1 |
De Mattia, G | 1 |
Matsumoto, K | 3 |
Sera, Y | 2 |
Abe, Y | 2 |
Tominaga, T | 2 |
Ueki, Y | 1 |
Miyake, S | 2 |
Frey, N | 2 |
Laveille, C | 2 |
Paraire, M | 1 |
Francillard, M | 1 |
Holford, NH | 1 |
Jochemsen, R | 2 |
Bahadori, B | 1 |
Trinker, M | 1 |
Wallner, SJ | 1 |
Yazdani-Biuki, B | 1 |
Wascher, TC | 2 |
Banerjee, S | 1 |
Sinharoy, K | 1 |
Zhu, XX | 1 |
Shi, HL | 1 |
Yang, WY | 2 |
Jiang, J | 1 |
Sun, XC | 1 |
Davies, C | 1 |
Chow, WH | 1 |
Stefanović, V | 2 |
Antić, S | 2 |
Mitić-Zlatković, M | 1 |
Stojiljković, S | 1 |
Milojković, M | 2 |
Bogicević, M | 1 |
Vlahović, P | 2 |
Dhindsa, P | 1 |
Davis, KR | 1 |
Donnelly, R | 1 |
Schernthaner, G | 5 |
Starkey, BJ | 1 |
Powell, RJ | 1 |
Gribble, FM | 1 |
Clark, PM | 1 |
Hattersley, AT | 1 |
Ramachandran, A | 1 |
Furlong, NJ | 1 |
Hulme, SA | 1 |
O'Brien, SV | 1 |
Hardy, KJ | 1 |
Scheen, AJ | 1 |
Lawrence, JM | 1 |
Reid, J | 1 |
Taylor, GJ | 1 |
Stirling, C | 1 |
Reckless, JP | 1 |
Yanagawa, T | 1 |
Araki, A | 1 |
Sasamoto, K | 1 |
Shirabe, S | 1 |
Yamanouchi, T | 2 |
Guillausseau, PJ | 4 |
Campbell, IW | 1 |
Yeki, Y | 1 |
Crawford, BA | 1 |
Perera, C | 1 |
Baksi, A | 2 |
James, RE | 1 |
Zhou, B | 1 |
Nolan, JJ | 1 |
Grimaldi, A | 1 |
Di Mario, U | 1 |
Drzewoski, J | 3 |
Kempler, P | 1 |
Kvapil, M | 1 |
Novials, A | 1 |
Rottiers, R | 1 |
Rutten, GE | 1 |
Shaw, KM | 2 |
Gao, Y | 1 |
Yuan, SY | 1 |
Xing, XY | 1 |
Guo, XH | 1 |
Li, HB | 1 |
Miwa, S | 1 |
Watada, H | 1 |
Ohmura, C | 1 |
Tanaka, Y | 1 |
Kawamori, R | 1 |
Drouin, P | 2 |
Standl, E | 1 |
Stalder, Dde M | 1 |
Belcher, G | 3 |
Lambert, C | 2 |
Goh, KL | 1 |
Edwards, G | 4 |
Valbuena, M | 1 |
Gavrilă, L | 1 |
Brădescu, OM | 1 |
Guja, C | 1 |
Singhal, P | 1 |
Caumo, A | 1 |
Cobelli, C | 1 |
Taylor, R | 3 |
Katakami, N | 1 |
Yamasaki, Y | 1 |
Hayaishi-Okano, R | 1 |
Ohtoshi, K | 1 |
Kaneto, H | 1 |
Matsuhisa, M | 1 |
Kosugi, K | 1 |
Hori, M | 1 |
Khan, M | 1 |
Xu, Y | 1 |
Urquhart, R | 6 |
Boes, U | 1 |
Tan, MH | 2 |
Krahulec, B | 1 |
Kubalski, P | 1 |
Stankiewicz, A | 1 |
Johns, D | 2 |
Charbonnel, B | 2 |
Mihm, M | 1 |
Widel, M | 1 |
Tan, M | 1 |
Emral, R | 1 |
Köseoğlulari, O | 1 |
Tonyukuk, V | 1 |
Uysal, AR | 1 |
Kamel, N | 1 |
Corapçioğlu, D | 1 |
Charbonnel, BH | 1 |
Hanefeld, M | 2 |
Brunetti, P | 4 |
Hartsleben, ChH | 1 |
Battegay, E | 1 |
Schumm-Draeger, PM | 1 |
Inukai, K | 1 |
Watanabe, M | 1 |
Nakashima, Y | 1 |
Sawa, T | 1 |
Takata, N | 1 |
Tanaka, M | 1 |
Kashiwabara, H | 1 |
Yokota, K | 1 |
Suzuki, M | 1 |
Kurihara, S | 1 |
Awata, T | 2 |
Katayama, S | 2 |
Satoh, J | 1 |
Takahashi, K | 2 |
Takizawa, Y | 1 |
Ishihara, H | 1 |
Hirai, M | 1 |
Katagiri, H | 1 |
Hinokio, Y | 1 |
Suzuki, S | 2 |
Tsuji, I | 1 |
Oka, Y | 1 |
Whitelaw, D | 1 |
Kardas, P | 1 |
Betteridge, DJ | 1 |
Vergès, B | 1 |
Ning, G | 1 |
Gao, X | 1 |
Yang, HZ | 1 |
Li, M | 1 |
Hong, J | 1 |
Lu, ZQ | 1 |
Qi, YQ | 1 |
Li, ZW | 1 |
Xiang, KS | 1 |
Lu, CH | 1 |
Chang, CC | 1 |
Chuang, LM | 1 |
Wang, CY | 2 |
Jiang, YD | 1 |
Wu, HP | 1 |
Perriello, G | 2 |
Pampanelli, S | 2 |
Di Pietro, C | 2 |
de Winter, W | 1 |
DeJongh, J | 1 |
Post, T | 1 |
Ploeger, B | 1 |
Moules, I | 1 |
Eckland, D | 1 |
Danhof, M | 1 |
Pan, NH | 1 |
Lee, TM | 1 |
Lin, MS | 1 |
Huang, CL | 1 |
Chang, NC | 1 |
Ceriello, A | 2 |
Lazarević, G | 1 |
Brown, N | 1 |
Ristic, S | 2 |
Collober-Maugeais, C | 2 |
Pecher, E | 2 |
Cressier, F | 2 |
Papanas, N | 1 |
Tziakas, D | 1 |
Chalikias, G | 1 |
Floros, D | 1 |
Trypsianis, G | 1 |
Papadopoulou, E | 1 |
Kortsaris, A | 1 |
Symeonidis, G | 1 |
Souliou, E | 1 |
Maltezos, E | 1 |
Hatseras, D | 1 |
Xue, J | 1 |
Liu, M | 1 |
Chen, JH | 1 |
Zurawska-Klis, M | 1 |
Liu, X | 1 |
Kuang, H | 1 |
Yi, R | 1 |
Lemenuel-Diot, A | 1 |
Mallet, A | 1 |
Räkel, A | 1 |
Renier, G | 3 |
Roussin, A | 1 |
Buithieu, J | 1 |
Mamputu, JC | 1 |
Serri, O | 3 |
Barchielli, A | 1 |
Masotti, G | 1 |
Buiatti, E | 1 |
Mendes, GD | 1 |
Moreira, LD | 1 |
Pereira, Ados S | 1 |
Borges, A | 1 |
Yui, F | 1 |
Mendes, FD | 1 |
de Nucci, G | 1 |
Lei, WY | 1 |
Wang, TE | 1 |
Chen, TL | 1 |
Chang, WH | 1 |
Yang, TL | 1 |
Tang, P | 1 |
Bilinska, M | 1 |
Potocka, J | 1 |
Korzeniowska-Kubacka, I | 1 |
Piotrowicz, R | 1 |
Khanolkar, MP | 1 |
Morris, RH | 1 |
Thomas, AW | 1 |
Bolusani, H | 1 |
Roberts, AW | 1 |
Geen, J | 1 |
Jackson, SK | 1 |
Evans, LM | 1 |
Sena, CM | 1 |
Louro, T | 1 |
Matafome, P | 1 |
Nunes, E | 1 |
Monteiro, P | 1 |
Seiça, R | 1 |
Sliwinska, A | 1 |
Blasiak, J | 1 |
Kasznicki, J | 1 |
Barnett, AH | 2 |
Krentz, AJ | 1 |
Strojek, K | 3 |
Sieradzki, J | 1 |
Azizi, F | 1 |
Embong, M | 1 |
Imamoglu, S | 1 |
Perusicová, J | 1 |
Uliciansky, V | 1 |
Lesobre, B | 9 |
Sullivan, JT | 1 |
Smith, RB | 1 |
Golay, A | 1 |
Broquet, C | 1 |
Chabot, V | 1 |
Studer, S | 1 |
Felber, JP | 1 |
Brogard, JM | 1 |
Pinget, M | 1 |
Dorner, M | 1 |
Almér, LO | 1 |
Minami, N | 1 |
Ikeda, Y | 1 |
Abe, M | 1 |
Baba, S | 1 |
Nakagawa, S | 1 |
Takebe, K | 1 |
Goto, Y | 1 |
Maezawa, H | 1 |
Takeda, R | 1 |
Sakamoto, N | 2 |
Fukui, I | 1 |
Velikov, VK | 1 |
Shubina, IO | 1 |
Saltykov, BB | 1 |
Frolova, AI | 1 |
Robb, GH | 1 |
Lowe, SM | 1 |
Tsang, LW | 1 |
Sorensen, JP | 1 |
Cockram, CS | 1 |
Lunetta, M | 1 |
Di Mauro, M | 1 |
Crimi, S | 1 |
Mughini, L | 1 |
Sener, A | 1 |
Akkan, AG | 1 |
Malaisse, WJ | 1 |
Kumar, S | 1 |
Keswani, P | 1 |
Bose, BS | 1 |
Agrawal, JK | 1 |
Palmer, KJ | 1 |
Brogden, RN | 1 |
Akazawa, S | 1 |
Abiru, N | 1 |
Yano, M | 1 |
Ishibasi, M | 1 |
Uotani, S | 1 |
Matsuo, H | 1 |
Kawasaki, E | 1 |
Yamasaki, H | 1 |
Yamamoto, H | 1 |
Alberti, KG | 2 |
Vestergaard, H | 3 |
Weinreb, JE | 1 |
Rosen, AS | 1 |
Bjørbaek, C | 2 |
Hansen, L | 1 |
Pedersen, O | 4 |
Kahn, BB | 1 |
Tessier, D | 2 |
Dawson, K | 1 |
Tétrault, JP | 1 |
Bravo, G | 1 |
Meneilly, GS | 1 |
Sobenin, IA | 1 |
Maksumova, MA | 1 |
Slavina, ES | 1 |
Balabolkin, MI | 4 |
Orekhov, AN | 1 |
Seshiah, V | 1 |
Venkataraman, S | 1 |
Suresh, K | 1 |
Kamikubo, K | 1 |
Takami, R | 1 |
Suwa, T | 1 |
Sugiyama, A | 1 |
Horibe, N | 1 |
Sakata, S | 1 |
Wolffenbuttel, BH | 2 |
Nijst, L | 1 |
Sels, JP | 1 |
Menheere, PP | 1 |
Müller, PG | 1 |
Kruseman, AC | 1 |
Quatraro, A | 2 |
De Rosa, N | 1 |
Acampora, R | 1 |
Giugliano, D | 2 |
Chen, KW | 1 |
Juang, JH | 1 |
Huang, HS | 1 |
Huang, BY | 1 |
Huang, MJ | 1 |
Bresler, M | 1 |
Gumprecht, J | 1 |
Grzeszczak, W | 2 |
Trautsolt, W | 1 |
Wajchenberg, BL | 2 |
Santomauro, AT | 2 |
Porrelli, RN | 2 |
Zapecka-Dubno, B | 1 |
Wiśniewska, K | 1 |
Szczepanik, Z | 1 |
Kasperska-Czyzykowa, T | 1 |
Rupprecht, E | 1 |
König, E | 1 |
Limmer, J | 1 |
Tsumura, K | 1 |
Ogata, N | 1 |
Tagaya, T | 1 |
Kawasaki, T | 1 |
Sekino, N | 1 |
Funato, H | 1 |
Akaoka, L | 1 |
Miyashita, H | 1 |
Lund, S | 1 |
Yoshioka, K | 1 |
Riccio, A | 1 |
Lisato, G | 1 |
de Kreutzenberg, SV | 1 |
Marchetto, S | 2 |
Turrin, M | 1 |
Tiengo, A | 3 |
Del Prato, S | 2 |
Braatvedt, GD | 1 |
Inoue, I | 1 |
Noji, S | 1 |
Negishi, K | 1 |
Gregorio, F | 2 |
Ambrosi, F | 2 |
Manfrini, S | 2 |
Santucci, A | 1 |
Filipponi, P | 2 |
Rachman, J | 1 |
Levy, JC | 1 |
Barrow, BA | 1 |
Manley, SE | 2 |
Turner, RC | 4 |
Kaneko, T | 1 |
Boland, O | 1 |
O'Brien, RC | 1 |
Luo, M | 1 |
Cathelineau, G | 1 |
de Champvallins, M | 1 |
Bouallouche, A | 1 |
Hammersley, MS | 2 |
Meyer, LC | 1 |
Morris, RJ | 2 |
Holman, RR | 2 |
Karunakaran, S | 1 |
Rabbone, I | 1 |
Piccinini, M | 1 |
Curto, M | 1 |
Mostert, M | 1 |
Gamba, S | 1 |
Mioletti, S | 1 |
Bruno, R | 1 |
Rinaudo, MT | 1 |
Desfaits, AC | 2 |
Bardini, G | 1 |
Rotella, CM | 1 |
Dachicourt, N | 1 |
Bailbé, D | 2 |
Gangnerau, MN | 1 |
Serradas, P | 3 |
Ravel, D | 1 |
Portha, B | 3 |
Muggeo, M | 1 |
Galeone, F | 2 |
Fiore, G | 2 |
Arcangeli, A | 1 |
Elhadd, TA | 1 |
Newton, RW | 1 |
Jennings, PE | 6 |
Belch, JJ | 4 |
Ammari, F | 1 |
Koppiker, N | 1 |
Gregory, R | 1 |
Burden, AC | 1 |
Maheux, P | 1 |
Khalil, A | 1 |
Fülöp, T | 1 |
Güvener, N | 1 |
Gedik, O | 1 |
Dourakis, SP | 1 |
Tzemanakis, E | 1 |
Sinani, C | 1 |
Kafiri, G | 1 |
Hadziyannis, SJ | 1 |
Velussi, M | 1 |
Carle, F | 1 |
Testa, R | 1 |
Merante, D | 1 |
Gomis, R | 1 |
Squatrito, S | 1 |
Jones, NP | 1 |
Patwardhan, RN | 1 |
Tzanakis, N | 1 |
Bouros, D | 1 |
Siafakas, N | 1 |
Davis, TM | 1 |
Daly, F | 1 |
Walsh, JP | 1 |
Ilett, KF | 1 |
Beilby, JP | 1 |
Dusci, LJ | 1 |
Barrett, PH | 1 |
Tripathi, BK | 1 |
Gougeon, R | 1 |
Styhler, K | 1 |
Morais, JA | 1 |
Jones, PJ | 1 |
Marliss, EB | 1 |
de Smet, PA | 1 |
Fischer, HR | 1 |
Kihara, Y | 1 |
Otsuki, M | 1 |
Paroni, R | 1 |
Comuzzi, B | 1 |
Arcelloni, C | 1 |
Brocco, S | 1 |
de Kreutzenberg, S | 1 |
Ciucci, A | 1 |
Beck-Peccoz, P | 1 |
Genovese, S | 1 |
Cerasi, E | 4 |
Harrower, A | 1 |
Crepaldi, G | 1 |
Fioretto, P | 1 |
Alagözlü, H | 1 |
Gültekin, F | 1 |
Candan, F | 1 |
Chazan, AC | 1 |
Gomes, MB | 1 |
Shustov, SB | 1 |
Romashevskiĭ, BV | 1 |
Khalimov, IuSh | 1 |
Stepanova, OIu | 1 |
Lysenko, AG | 1 |
Salman, S | 1 |
Salman, F | 1 |
Yilmaz, Y | 1 |
Ozer, E | 1 |
Sengül, A | 1 |
Demirel, HO | 1 |
Karşidağ, K | 1 |
Dinççağ, N | 1 |
Yilmaz, MT | 1 |
van der Wal, PS | 1 |
Heine, RJ | 1 |
Spallarossa, P | 1 |
Schiavo, M | 1 |
Rossettin, P | 1 |
Cordone, S | 1 |
Olivotti, L | 1 |
Cordera, R | 1 |
Brunelli, C | 1 |
Greb, W | 1 |
da Tos, V | 1 |
Maran, A | 1 |
Vigili de Kreutzenberg, S | 1 |
Tadiotto, F | 1 |
Bettio, M | 1 |
Marescotti, MC | 1 |
Ligtenberg, JJ | 1 |
Reitsma, WD | 1 |
van Haeften, TW | 1 |
Juhl, CB | 1 |
Pørksen, N | 1 |
Pincus, SM | 1 |
Hansen , AP | 1 |
Veldhuis, JD | 1 |
Schmitz, O | 2 |
Bratholm, P | 1 |
Christensen, NJ | 1 |
Chugh, SN | 1 |
Dhawan, R | 1 |
Kishore, K | 1 |
Sharma, A | 1 |
Chugh, K | 1 |
McGavin, JK | 1 |
Perry, CM | 1 |
Goa, KL | 1 |
Cho, YW | 1 |
Oh, DY | 1 |
Baick, SH | 1 |
Kim, SK | 1 |
Kim, SJ | 1 |
Hong, SY | 1 |
Pugh, JA | 1 |
Wagner, ML | 1 |
Sawyer, J | 1 |
Ramirez, G | 1 |
Tuley, M | 1 |
Friedberg, SJ | 1 |
Giannella-Neto, D | 1 |
Borghi, VC | 1 |
Aschner, P | 1 |
Kattah, W | 1 |
Roblin, X | 1 |
Abinader, Y | 1 |
Baziz, A | 1 |
Phenekos, C | 1 |
Siafaka-Kapadai, A | 1 |
Trapali, M | 1 |
Botitsi, E | 1 |
Mavris, M | 1 |
Fu, ZZ | 1 |
Yan, T | 1 |
Chen, YJ | 1 |
Sang, JQ | 1 |
Scott, NA | 1 |
Saniabadi, AR | 1 |
Johnson, AB | 2 |
Krall, LP | 1 |
Campbell, DB | 2 |
Lavielle, R | 2 |
Nathan, C | 1 |
Chiasson, JL | 1 |
Verdy, M | 1 |
Hosker, JP | 2 |
Stratton, I | 1 |
Bak, JF | 2 |
Harrower, AD | 3 |
Della Casa, L | 2 |
del Rio, G | 2 |
Glaser, B | 2 |
Kilo, C | 1 |
Dudley, J | 1 |
Kalb, B | 1 |
Ziegler, O | 1 |
Argyraki, M | 1 |
Thow, JC | 1 |
Jones, IR | 1 |
Broughton, D | 1 |
Miller, M | 1 |
Kawai, K | 1 |
Murayama, Y | 1 |
Watanabe, Y | 1 |
Yamashita, K | 1 |
Colwell, JA | 1 |
Rifkin, H | 1 |
Marquié, G | 1 |
Hadjiisky, P | 1 |
Arnaud, O | 1 |
Duhault, J | 1 |
Akanuma, Y | 2 |
Kosaka, K | 2 |
Kanazawa, Y | 2 |
Kasuga, M | 2 |
Fukuda, M | 2 |
Aoki, S | 2 |
Gram, J | 2 |
Jespersen, J | 2 |
Noury, J | 1 |
Nandeuil, A | 1 |
Monges, AM | 1 |
Pisano, P | 1 |
Aujoulat, P | 1 |
Salducci, D | 1 |
Durand, A | 1 |
Panagides, D | 1 |
Bory, M | 1 |
Crevat, A | 1 |
Wong, C | 1 |
Chang, TC | 1 |
Wang, LM | 1 |
Cheng, CY | 1 |
Kuo, HF | 1 |
Liu, PC | 1 |
Ho, LT | 1 |
Batch, J | 1 |
Ma, A | 2 |
Bird, D | 2 |
Noble, R | 1 |
Charles, B | 1 |
Ravenscroft, P | 1 |
Cameron, D | 1 |
Ishibashi, F | 1 |
Takashina, S | 1 |
Kozlov, GS | 1 |
Buĭdina, TA | 1 |
Kold, A | 1 |
Sørensen, NS | 1 |
Rudenski, AS | 1 |
Burnett, MA | 1 |
Kamp, M | 1 |
Howlett, V | 1 |
Cameron, DP | 1 |
Conget, JI | 1 |
Vendrell, J | 1 |
Esmatjes, E | 1 |
Halperin, I | 1 |
Paterson, KR | 1 |
Gyi, KM | 1 |
McBride, D | 1 |
Cohen, HN | 1 |
Shenkin, A | 1 |
Manderson, WG | 1 |
MacCuish, AC | 1 |
Wheeley, MS | 1 |
Ward, JD | 1 |
Procacci, V | 1 |
Giovine, A | 1 |
Roberto, MG | 1 |
Di Reda, N | 1 |
Lasorsa, G | 1 |
Vendemiale, G | 1 |
Stufano, N | 1 |
Altomare, E | 1 |
Wajchenberg, BJ | 1 |
Santomaruo, AT | 1 |
Cherem, JJ | 1 |
Malerbi, DA | 1 |
Giurno Filho, A | 1 |
Lerario, AC | 1 |
Giannella Neto, D | 1 |
Larkins, RG | 1 |
Jerums, G | 1 |
Taft, JL | 1 |
Godfrey, H | 1 |
Smith, IL | 1 |
Martin, TJ | 1 |
Cortinovis, A | 1 |
Crippa, A | 1 |
Sciacca, V | 1 |
Caravaggio, V | 1 |
Crippa, M | 1 |
Florkowski, CM | 1 |
Richardson, MR | 1 |
Le Guen, C | 1 |
O'Donnell, MJ | 1 |
Jones, AF | 1 |
Lunec, J | 1 |
Nedosugova, LV | 1 |
Giraudo, JR | 1 |
Fugante, M | 1 |
Blaque Quadri, J | 1 |
Reyes, G | 1 |
Duran Saucedo, N | 1 |
McAlpine, LG | 1 |
McAlpine, CH | 1 |
Waclawski, ER | 1 |
Storer, AM | 1 |
Kay, JW | 1 |
Frier, BM | 1 |
Morozova, TP | 1 |
Chachiashvili, MV | 1 |
Frühwald, T | 1 |
Böhmer, F | 1 |
Patel, JC | 1 |
Vikani, AV | 1 |
Svoboda, Z | 1 |
Consoli, G | 1 |
Zurro Hernandez, J | 1 |
Ward, G | 1 |
Harrison, LC | 1 |
Proietto, J | 1 |
Aitken, P | 1 |
Nankervis, A | 1 |
Donatelli, M | 1 |
Sinagra, D | 1 |
Russo, V | 1 |
Bucalo, ML | 1 |
Giardina, E | 1 |
Cerasola, GA | 1 |
Bompiani, G | 1 |
Delargy, M | 1 |
McGovern, M | 1 |
Johnson, A | 1 |
Tomkin, GH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286] | 8,494 participants (Actual) | Observational | 2010-01-31 | Completed | |||
A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus[NCT02682563] | Phase 4 | 44 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
Study of Sulphonylurea Synergy With Incretins[NCT03705195] | 20 participants (Actual) | Interventional | 2018-08-03 | Completed | |||
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380] | Phase 4 | 557 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus[NCT00736515] | Phase 4 | 160 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty[NCT01709305] | Phase 4 | 5,570 participants (Actual) | Interventional | 2012-11-08 | Completed | ||
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572] | 200 participants (Anticipated) | Observational | 2012-01-31 | Active, not recruiting | |||
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891] | 160 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | |||
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559] | Phase 4 | 135 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309] | 465 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122] | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | |||
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose- A Double-blind, Placebo-controlled Clinical Research[NCT05737342] | 80 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | |||
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes[NCT00102388] | Phase 3 | 1,092 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes[NCT01238380] | 1,916 participants (Actual) | Observational | 2010-12-31 | Completed | |||
Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measured in kilograms (NCT02682563)
Timeframe: 12 weeks
Intervention | kilograms (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 93.7 |
Gliclazide Modified Release 30mg Once Daily | 99.6 |
Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min (NCT02682563)
Timeframe: 12 weeks
Intervention | ml/min (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 639 |
Gliclazide Modified Release 30mg Once Daily | 678 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose (NCT02682563)
Timeframe: 12 weeks
Intervention | % of filtered glucose (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 31.1 |
Gliclazide Modified Release 30mg Once Daily | 0.6 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium (NCT02682563)
Timeframe: 12 weeks
Intervention | % of filtered potassium (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 13.6 |
Gliclazide Modified Release 30mg Once Daily | 11.8 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium (NCT02682563)
Timeframe: 12 weeks
Intervention | % of filtered sodium (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 0.74 |
Gliclazide Modified Release 30mg Once Daily | 0.66 |
Calculated from urinary and plasma inulin concentrations, GFR in ml/min (NCT02682563)
Timeframe: 12 weeks
Intervention | ml/min (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 104 |
Gliclazide Modified Release 30mg Once Daily | 109 |
KIM-1 (ng/mmol) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
Intervention | ng/mmol (Median) |
---|---|
Dapagliflozin 10mg Once Daily | 0.25 |
Gliclazide Modified Release 30mg Once Daily | 0.265 |
NGAL (ng/mmoll) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
Intervention | ng/mmol (Median) |
---|---|
Dapagliflozin 10mg Once Daily | 3.76 |
Gliclazide Modified Release 30mg Once Daily | 3.79 |
Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg (NCT02682563)
Timeframe: 12 weeks
Intervention | mmHg (Mean) |
---|---|
Dapagliflozin 10mg Once Daily | 129.2 |
Gliclazide Modified Release 30mg Once Daily | 131.1 |
Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol (NCT02682563)
Timeframe: 12 weeks
Intervention | mg/mmol (Median) |
---|---|
Dapagliflozin 10mg Once Daily | 0.88 |
Gliclazide Modified Release 30mg Once Daily | 0.54 |
HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44
Intervention | Percent (Least Squares Mean) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | -0.65 |
Phase 2: Metformin + Sitagliptin + Repaglinide | -0.62 |
Phase 2: Metformin + Sitagliptin + Acarbose | -0.46 |
Phase 2: Metformin + Sitagliptin + Gliclazide | -0.69 |
Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44
Intervention | kg (Mean) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 0.4 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 0.2 |
Phase 2: Metformin + Sitagliptin + Acarbose | -0.9 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
Intervention | Percentage of Participants (Number) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 0 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
Intervention | Percentage of Participants (Number) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 0 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
Intervention | Percentage of Participants (Number) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 0.5 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 0.4 |
Phase 2: Metformin + Sitagliptin + Acarbose | 0.4 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 0.9 |
"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44
Intervention | Percentage of Participants (Number) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 0.2 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 0 |
Phase 2: Metformin + Sitagliptin + Acarbose | 0.2 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 0.2 |
Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44
Intervention | Percentage of Participants (Number) |
---|---|
Phase 2: Metformin + Sitagliptin + Glimepiride | 8.9 |
Phase 2: Metformin + Sitagliptin + Repaglinide | 6.1 |
Phase 2: Metformin + Sitagliptin + Acarbose | 0.5 |
Phase 2: Metformin + Sitagliptin + Gliclazide | 3.6 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
Intervention | percentage (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -2.43 |
Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | % of HbA1C (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | 7.1 |
Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
Intervention | Participants (Count of Participants) |
---|---|
Insulin Glargine, Metformin, Exenatide | 0 |
Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | kg (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -4.8 |
Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | µg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | -0.2 |
Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | mmHg (Median) |
---|---|
Sitagliptin | 4 |
Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | 0.1 |
Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 3 |
Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 9.5 |
Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | kg (Median) |
---|---|
Sitagliptin | -0.5 |
Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Gliclazide | -1.12 |
Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Sitagliptin | 3.41 |
Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | -0.07 |
Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
Intervention | Participants (Count of Participants) |
---|---|
Sitagliptin | 6 |
Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) | ||||
---|---|---|---|---|---|
DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
PASI 50 | PASI 75 | PASI 90 | |
Gliclazide | 1 | 0 | 0 |
Sitagliptin | 1 | 0 | 0 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mmol/l (Mean) | |
---|---|---|
Baseline FSG | 3rd Month FSG | |
Metformin ( 002 Group) | 6.2 | 6.5 |
Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | μU/ml (Mean) | |
---|---|---|
Baseline FSI | 3rd month FSI | |
Metformin ( 002 Group) | 13.0 | 13.9 |
Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |
---|---|---|
Baseline HbA1c | 3rd month HbA1c | |
Metformin ( 002 Group) | 7.8 | 7.0 |
Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |||
---|---|---|---|---|
Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | Score on a scale ( SI unit) (Mean) | |||
---|---|---|---|---|
Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mg/dl (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
Intervention | Ratio (Mean) |
---|---|
Pioglitazone Group | 1.02 |
Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
Intervention | % Change (Mean) | |||
---|---|---|---|---|
% Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
50 reviews available for gliclazide and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Comp | 2022 |
ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Feasibility Studies; Gliclazide; Glycemic Control; Humans; | 2020 |
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds | 2018 |
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Rela | 2019 |
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2013 |
Liuwei dihuang pills enhance the effect of Western medicine in treating type 2 diabetes: A meta-analysis of randomized controlled trials.
Topics: Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Fasting; Glic | 2013 |
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gliclazide; Humans; Hu | 2015 |
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gliclazide; H | 2015 |
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glicl | 2015 |
Is gliclazide a sulfonylurea with difference? A review in 2016.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Prac | 2016 |
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development.
Topics: Biological Products; Diabetes Mellitus, Type 2; Drug Discovery; Gliclazide; Glucose Transporter Type | 2018 |
Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.
Topics: Acarbose; Aged; Autoimmune Diseases; Diabetes Mellitus, Type 2; Drug Substitution; Gliclazide; Human | 2016 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe | 2012 |
[Hypoglycemia].
Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Treating diabetes today with gliclazide MR: a matter of numbers.
Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne | 2012 |
Role of K(ATP) channels in β-cell resistance to oxidative stress.
Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation, Enzymologic | 2012 |
Oral hypoglycaemic agent failure.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hem | 2002 |
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration S | 2003 |
[Medication of the month. Gliclazide modified release (Uni Diamicron)].
Topics: Administration, Oral; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hy | 2003 |
Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metfo | 2004 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl | 2004 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli | 2005 |
Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
Topics: Adult; Aged; Asian People; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Do | 2006 |
Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Likelihood Functi | 2007 |
New insights from ADVANCE.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus, T | 2007 |
[Diabetic retinopathy. Effects of gliclazide].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo | 1983 |
[Non-insulin dependent diabetes. Role of gliclazide (diamicron)].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gliclazide; Humans; Male | 1995 |
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Drug | 1993 |
[Gliclazide: review of metabolic and vascular action].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Gliclazide; Glucose; Humans | 1994 |
[Clinical efficacy of glimepiride].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Insuli | 1997 |
[Timing of administration of sulfonyl urea derivatives].
Topics: Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administr | 2000 |
Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
Topics: ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hyp | 2000 |
Vascular benefits of gliclazide beyond glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Glic | 2000 |
Gliclazide modified release: its place in the therapeutic armamentarium.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Islets | 2000 |
Gliclazide modified release.
Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gliclazide | 2002 |
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic | 1992 |
Gliclazide: metabolic and vascular effects--a perspective.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul | 1992 |
The treatment of NIDDM in the decade of the 90s.
Topics: Diabetes Mellitus, Type 2; Diet, Diabetic; Forecasting; Gliclazide; Humans; Insulin; Sulfonylurea Co | 1991 |
The mode of action and clinical pharmacology of gliclazide: a review.
Topics: Adult; Aged; Animals; Diabetes Mellitus, Type 2; Gliclazide; Humans; Islets of Langerhans; Platelet | 1991 |
Gliclazide and insulin action in human muscle.
Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glycogen; Humans; Insulin; Muscles | 1991 |
Hemobiological activity of gliclazide in diabetes mellitus.
Topics: Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Platelet Adhe | 1991 |
Current status of non-insulin-dependent diabetes mellitus (type II): management with gliclazide.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Exercise; Gliclazide; Humans; Insulin | 1991 |
[Glycogen synthetase and non-insulin-dependent diabetes: role of gliclazide].
Topics: Biopsy; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Glycogen Synthase; Humans; | 1991 |
[Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron].
Topics: Animals; Arteriosclerosis; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endoth | 1990 |
[Physiopathology of non insulin-dependent diabetes. Action of gliclazide].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion | 1985 |
[Diamicron through the European Association for the Study of Diabetes and the International Diabetes Federation congresses in Sydney in 1988].
Topics: Animals; Australia; Diabetes Mellitus, Type 2; Gliclazide; Humans; Paris; Rats; Sulfonylurea Compoun | 1989 |
[Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; In | 1988 |
157 trials available for gliclazide and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
Topics: Adult; Aged; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations | 2022 |
Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hyperkalemi | 2022 |
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; | 2020 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; | 2020 |
Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fe | 2020 |
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 2020 |
Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Gliclazide; Glomerular Filtration Rate; Glucosides; | 2020 |
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrat | 2020 |
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Topics: Adipose Tissue; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyc | 2017 |
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; | 2018 |
Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Topics: Aged; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Gliclazide; Glycated Hemoglob | 2019 |
A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2
Topics: Adamantane; Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Brazil; Delayed-Action Prepar | 2018 |
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Fem | 2019 |
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, | 2019 |
Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Glicla | 2019 |
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T | 2014 |
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2014 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2014 |
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogly | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip | 2014 |
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow | 2014 |
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell | 2015 |
Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; China; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2015 |
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2015 |
Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Respons | 2016 |
Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Topics: Adamantane; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dipeptides; Dipepti | 2016 |
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin | 2016 |
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F | 2016 |
Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Comorbidity; Cross-Over Studies; Diabetes Mellitus, Typ | 2016 |
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld | 2017 |
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea | 2016 |
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.
Topics: Alleles; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Female; Genotype; Gliclazide | 2017 |
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2017 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female | 2008 |
Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Administra | 2008 |
Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fa | 2009 |
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2009 |
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
Topics: Adamantane; Demography; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glicl | 2009 |
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mell | 2010 |
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mell | 2010 |
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2010 |
The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agent | 2010 |
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The | 2010 |
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes M | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.
Topics: Adult; Biomarkers; Cell Movement; Cells, Cultured; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2010 |
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A | 2010 |
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Topics: Adult; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazid | 2011 |
Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Antioxidants; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascu | 2011 |
AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study.
Topics: Aged; AMP-Activated Protein Kinases; Cross-Over Studies; Diabetes Mellitus, Type 2; Gliclazide; Huma | 2011 |
Intensive glucose control and risk of cancer in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Ins | 2011 |
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
Topics: Aged; Asia; Australia; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Euro | 2011 |
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; | 2012 |
Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
Topics: Adult; Aged; Antioxidants; Arginine; Blood Pressure; Diabetes Mellitus, Type 2; Free Radicals; Glicl | 2002 |
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glic | 2002 |
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Relationship, Drug; Fem | 2003 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2003 |
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind | 2003 |
Genetic cause of hyperglycaemia and response to treatment in diabetes.
Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, | 2003 |
Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; | 2003 |
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2003 |
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated | 2004 |
Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Deoxyglucose; D | 2004 |
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2004 |
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp | 2004 |
[The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
Topics: Adult; Aged; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyp | 2004 |
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Topics: Adult; Cross-Over Studies; Cyclohexanes; Deoxyglucose; Diabetes Mellitus, Type 2; Gliclazide; Glycat | 2004 |
Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Metho | 2004 |
NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.
Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Chole | 2004 |
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucag | 2005 |
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
Topics: Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2004 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2005 |
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glyc | 2005 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me | 2005 |
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administ | 2005 |
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Gl | 2005 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
Topics: Age of Onset; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glic | 2005 |
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; | 2005 |
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated He | 2005 |
The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
Topics: Adult; Aged; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; | 2005 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
[A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged | 2005 |
Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
Topics: Adult; Aged; Asian People; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Do | 2006 |
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Female | 2006 |
Association of gliclazide and left ventricular mass in type 2 diabetic patients.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Electrocardiography; Female; Gliclazide; Glyburide | 2006 |
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
ADVANCE: breaking new ground in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics | 2006 |
Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Glycated Hemoglobin; | 2006 |
Clinical observation on effect of Kaixin capsule in treating 40 patients with diabetic myocardial ischemia.
Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Elec | 2006 |
Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin | 2006 |
Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.
Topics: Adult; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype | 2007 |
Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Gliclazi | 2007 |
A bioequivalence study of gliclazide based on quantification by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Topics: Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Sta | 2007 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal | 2007 |
'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
Topics: Angina Pectoris; Blood Pressure; Diabetes Mellitus, Type 2; Exercise; Gliclazide; Glyburide; Heart R | 2007 |
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Topics: Adult; Aged; Blood Glucose; Blood Platelets; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Gliclaz | 2008 |
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2007 |
The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Typ | 2008 |
[Diabetic retinopathy. Effects of gliclazide].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans; Sulfo | 1983 |
Gliclazide: a new sulphonylurea.
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle | 1984 |
Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Retinopath | 1983 |
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholestero | 1995 |
No important differences in glycaemic responses to common fruits in type 2 diabetic patients.
Topics: Analysis of Variance; Bread; Citrus; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrate | 1995 |
Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting | 1994 |
Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Humans; Hypoglycemia; | 1994 |
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glybur | 1993 |
Combination therapy in NIDDM.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glic | 1993 |
Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gliclazide; Glyca | 1995 |
Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
Topics: Biomarkers; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Ev | 1996 |
Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; | 1996 |
Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; | 1997 |
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
Topics: Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2 | 1997 |
Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Fast | 1997 |
The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Topics: Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Respon | 1997 |
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St | 1997 |
The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Fructosamin | 1997 |
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Gliclazide; | 1997 |
Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia.
Topics: Blood Glucose; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyp | 1998 |
[Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; | 1998 |
The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
Topics: Adult; Aged; Asia, Southeastern; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic | 1999 |
Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Lipid | 1999 |
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellit | 1999 |
Medium-term hypoglycaemic effects of two different oral formulations of gliclazide.
Topics: Adult; Aged; Blood Glucose; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Female; Gliclazide | 1999 |
Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.
Topics: Aged; Aging; Antithrombin III; Blood Glucose; Blood Platelets; Cholesterol, HDL; Cholesterol, LDL; D | 1999 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mel | 2000 |
Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
Topics: Adult; Aged; Blood Platelets; Collagen; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2000 |
Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.
Topics: Adult; Aged; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogl | 2000 |
Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug | 2001 |
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
Topics: Acarbose; Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; | 2001 |
Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; H | 2001 |
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic; | 2001 |
24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Circadian Rhythm; Delayed-Action Preparations; Diabetes | 2001 |
Mechanisms of acute and chronic hypoglycemic action of gliclazide.
Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Glu | 2000 |
Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; | 2001 |
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug A | 2001 |
[Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Follow-Up Studies; Free Radical Scavengers; G | 2001 |
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Diabetes Mellitus, Type 2; Diabe | 2001 |
Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glyburide; Humans; Hypoglycemic | 2001 |
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic | 1992 |
Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Diabetes Mellitus, Type 2; Free Radical Scavenge | 1992 |
The physiological action of gliclazide: beta-cell function and insulin resistance.
Topics: Amino Acids; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clam | 1991 |
Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Diet, Diabetic; Gliclazide; Glipizide; Gly | 1991 |
The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Gl | 1991 |
Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Humans | 1991 |
Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Hum | 1991 |
Comparison of secondary failure rate between three second generation sulphonylureas.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Follow-Up Studies; Gliclazide; Glipizide; | 1990 |
The action of gliclazide on insulin secretion and insulin sensitivity in non-obese non-insulin dependent diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose Tolerance Test; Humans; I | 1990 |
Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1988 |
[Diamicron in the treatment of diabetes mellitus type 2].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic A | 1987 |
Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diet, Diabetic; Female; Gliclazide; Humans; Hypogly | 1988 |
Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow- | 1986 |
Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
Topics: Aged; Chlorpropamide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Gl | 1985 |
195 other studies available for gliclazide and Diabetes Mellitus, Adult-Onset
Article | Year |
---|---|
Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dos | 2009 |
Evaluation of the effectiveness and tolerability of gliclazide modified release 60 mg in patients with type 2 diabetes observing fasting during Ramadan in Pakistan: An analysis from the global DIA-RAMADAN study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Humans; Hypoglycemic Agents; Islam; P | 2021 |
Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Heart Disease Risk F | 2022 |
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide; | 2023 |
Optimal dosing of gliclazide-A model-based approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose; Glycated Hemoglobin; Humans; Hypoglyc | 2023 |
Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds | 2023 |
Real-world evidence on health-related quality of life in patients with type 2 diabetes mellitus using sulphonylureas: An analysis of the Joint Asia Diabetes Evaluation (JADE) Register.
Topics: Adult; Asia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Gliclazide; Glycated Hemoglobin; Hu | 2023 |
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Prospective Studies | 2023 |
Preclinical and clinical results regarding the effects of a plant-based antidiabetic formulation versus well established antidiabetic molecules.
Topics: Aged; Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fem | 2019 |
Observational analyses from ADVANCE and ADVANCE-ON.
Topics: Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents | 2020 |
Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
Topics: Animals; Biological Availability; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diab | 2019 |
A case of severe relapsing sulphonylurea-induced hypoglycaemia.
Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemia; Middle Aged; Renal Insufficienc | 2019 |
Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes.
Topics: Animals; Bile Acids and Salts; Capsules; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glicl | 2020 |
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2020 |
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent | 2020 |
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hemoglobin; Humans | 2020 |
Visualized analysis and evaluation of simultaneous controlled release of metformin hydrochloride and gliclazide from sandwiched osmotic pump capsule.
Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dogs; Drug Delivery Systems; Glicla | 2020 |
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazid | 2020 |
Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Fatty Liver; Female; Follow-U | 2021 |
The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; | 2021 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformi | 2022 |
Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients' response to gliclazide-modified-release-treated.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Metabolic Networks and Pathways; | 2021 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combi | 2017 |
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Fem | 2017 |
Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Gl | 2017 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Female; Gas Chro | 2018 |
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; D | 2018 |
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide | 2018 |
Is gliclazide a new antidiabetic drug implicated in the pathogenesis of ocular mucous membrane pemphigoid?
Topics: Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Pemph | 2018 |
Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report.
Topics: Antifungal Agents; Diabetes Mellitus, Type 2; Drug Interactions; Fluconazole; Gliclazide; Humans; Hy | 2018 |
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; | 2018 |
Reactive Oxygen Species-mediated Degradation of Antidiabetic Compounds: Cytotoxic Implications of Their Photodegradation Products.
Topics: Animals; Biotransformation; Cell Survival; Chlorocebus aethiops; Diabetes Mellitus, Type 2; Gliclazi | 2018 |
Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Dosage Calcul | 2018 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
Refraction paradox in diabetics: an extreme case of transient hyperopia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; | 2013 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Topics: Acute Coronary Syndrome; Aged; Alberta; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Typ | 2014 |
Acute generalized exanthematous pustulosis induced by gliclazide: a case report.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Hum | 2013 |
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Combinations; Female; Gl | 2014 |
Parsimonious model for blood glucose level monitoring in type 2 diabetes patients.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide; | 2014 |
Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metform | 2014 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular | 2015 |
Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
Topics: Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agen | 2015 |
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem | 2015 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gl | 2016 |
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re | 2016 |
CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
Topics: Blood Glucose; China; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Genotype; Gliclazi | 2016 |
When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management.
Topics: Adult; Age of Onset; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; General Practice; G | 2016 |
A case of bullous pemphigoid ınduced by vildagliptin.
Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipepti | 2017 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations | 2016 |
Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study.
Topics: Adult; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2015 |
Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
Topics: Amino Acid Substitution; ATP-Binding Cassette Transporters; Blood Glucose; China; Cohort Studies; Di | 2008 |
Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes M | 2008 |
Sulphonylureas and cancer: a case-control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glybur | 2009 |
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypertension; Infant, Newborn; Live Bi | 2009 |
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti | 2009 |
Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.
Topics: Aged; Cholecystectomy; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypertension; Hypoglycemia; Ma | 2009 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl | 2009 |
Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Melli | 2009 |
Pioglitazone-induced acute rhabdomyolysis.
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Male; Muscl | 2009 |
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fastin | 2009 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A | 2009 |
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2009 |
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-Antiplasmin; Antithrombin III; Azides; Blood Glucose; Body Mass Index; Deoxyuracil Nuc | 2010 |
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
Topics: Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Family Practice; Gliclazide | 2010 |
Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
Topics: Adult; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Sc | 2010 |
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gli | 2010 |
[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Data Interpretation, Statis | 2010 |
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
Topics: Aged; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glipizide; Glybur | 2010 |
Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Glycogen; Lactic Acid; Male; Myocardial I | 2011 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Topics: Adamantane; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; | 2011 |
Diagnosis in diabetes: does it matter?
Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Glucokinase; Hepatocyte Nuclear Factor 1-alpha; Human | 2011 |
High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin.
Topics: Binding Sites; Binding, Competitive; Calibration; Carrier Proteins; Chromatography, Affinity; Diabet | 2011 |
Dissolution rate enhancement of gliclazide by ordered mixing.
Topics: Diabetes Mellitus, Type 2; Drug Carriers; Drug Compounding; Drug Delivery Systems; Excipients; Glicl | 2011 |
Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide | 2012 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Exp | 2012 |
Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus.
Topics: Blood Glucose; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female | 2012 |
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ | 2012 |
Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
Topics: Animals; Cell Death; Cell Line; Cluster Analysis; Diabetes Mellitus, Type 2; Gene Regulatory Network | 2012 |
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2012 |
Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazi | 2002 |
Diabetes mellitus and weight control: differences of respiratory quotient in type 2 diabetic obese subjects receiving sulfonylureas and non-diabetic obese controls.
Topics: Calorimetry, Indirect; Carbon Dioxide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclaz | 2003 |
Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
Topics: Acetylglucosaminidase; Administration, Oral; Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; Fem | 2003 |
[Compliance and optimisation of oral antidiabetic therapy. A longitudinal study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Chi-Square Distribution; Cohort | 2004 |
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ | 2004 |
Octreotide treatment for sulfonylurea-induced hypoglycaemia.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypogly | 2004 |
[Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Gliclazide; Glycated Hemogl | 2004 |
[Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dru | 2004 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Homeostasis; Humans; Hypoglycemic Age | 2005 |
[54-year-old patient with type 2 diabetes mellitus and increased blood pressure values].
Topics: Antihypertensive Agents; Blood Pressure Determination; Combined Modality Therapy; Coronary Disease; | 2005 |
Gliclazide modified release.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Gliclazide; Hu | 2005 |
Management of diabetes during Ramadan.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Gliclazide; Humans; | 2005 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type | 2006 |
Effects of gliclazide beyond metabolic control.
Topics: Antioxidants; Diabetes Complications; Diabetes Mellitus, Type 2; DNA Damage; Gliclazide; Humans; Hyp | 2006 |
Lymphocyte ecto-5'-nucleotidase in obese type 2 diabetic patients treated with gliclazide.
Topics: 5'-Nucleotidase; Adenosine; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2006 |
Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 diabetes patients suboptimally controlled with insulin.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin R | 2006 |
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2007 |
Insulinoma causing hypoglycemia in a patient with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglyc | 2007 |
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab | 2009 |
In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM).
Topics: Aged; Cell Separation; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; DNA Repair; Female; Glicl | 2008 |
[Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
Topics: Blood Glucose; Calorimetry, Indirect; Cholesterol; Diabetes Mellitus, Type 2; Energy Metabolism; Fem | 1984 |
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucagon; | 1984 |
Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes.
Topics: Aged; Chlorpropamide; Diabetes Mellitus, Type 2; Endothelium; Female; Fibrinogen; Fibrinolysis; Glic | 1984 |
Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gliclazide; Glyburide; Humans; | 1983 |
[Experience with diamicron treatment of diabetics].
Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evaluation; Dru | 1984 |
[Preliminary report on 30 cases of non-insulin-dependent diabetes (NIDD) treated with gliclazide].
Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle Aged; Sulfonylurea Compounds | 1983 |
Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male | 1984 |
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine; | 1995 |
Gliclazide in the treatment of obese NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Gliclazide; Human | 1994 |
Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
Topics: Adult; Aged; Base Sequence; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucose; Glucose Clamp Te | 1995 |
Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages.
Topics: Adult; Animals; Cells, Cultured; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 1994 |
Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans | 1993 |
Possible gliclazide-induced water retention with azotemia.
Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Edema; Female; | 1994 |
Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Islets of Langerhans; | 1993 |
[Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?].
Topics: Adult; Aged; Blood Platelets; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Mi | 1993 |
Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Tolerance Test; Humans | 1993 |
[Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Insul | 1993 |
[Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Sulfonylurea Compound | 1993 |
[Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Middle Aged; Platel | 1993 |
Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Topics: Adult; Aged; Animals; Base Sequence; Biopsy; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; DN | 1995 |
Elevation and fluctuation of serum CA 19-9 and SPAN-1 levels after administration of sulfonylurea in a diabetic patient with Lewis(a-,b-) blood phenotype.
Topics: Antigens, Neoplasm; Blood Glucose; CA-19-9 Antigen; Carcinoembryonic Antigen; Diabetes Mellitus, Typ | 1995 |
Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Hormones; Humans; Hypoglycemia; Hypogl | 1997 |
Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
Topics: Administration, Oral; Aged; Blood Glucose; Circadian Rhythm; Cohort Studies; Diabetes Mellitus, Type | 1997 |
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
Topics: Administration, Oral; Adult; Antioxidants; Ascorbic Acid; Coronary Artery Disease; Diabetes Mellitus | 1997 |
Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Lymphocy | 1998 |
Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
Topics: Animals; Aorta; Arteriosclerosis; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; C | 1998 |
Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glucose Toleran | 1998 |
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.
Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1998 |
Antioxidant effects of gliclazide and soluble adhesion molecules in type 2 diabetes.
Topics: Antioxidants; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Gliclazide; Humans; Solubility | 1999 |
Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evalua | 1998 |
Gliclazide-induced acute hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; | 2000 |
Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium.
Topics: Adult; Cell Adhesion; Cells, Cultured; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Gli | 2000 |
Eosinophilic pleural effusion due to gliclazide.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pleural Effus | 2000 |
Gliclazide, a better choice for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Treatment Outcome | 1999 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Interaction of gliclazide and rifampicin.
Topics: Aged; Antibiotics, Antitubercular; Clarithromycin; Diabetes Mellitus, Type 2; Drug Interactions; Dru | 2000 |
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores | 2000 |
Type 2 diabetes: to stimulate or not to stimulate the beta cell.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Isle | 2000 |
Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?
Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LD | 2000 |
[Reclid effects on carbohydrate, lipid metabolism, lipid peroxidation and hemodynamics in patients with diabetes mellitus type 2].
Topics: Carbohydrates; Diabetes Mellitus, Type 2; Female; Gliclazide; Hemodynamics; Humans; Hypoglycemic Age | 2000 |
Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.
Topics: Adult; Aged; Case-Control Studies; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; | 2001 |
Does gliclazide stimulate first-phase, second-phase, or both phases of insulin release?
Topics: Diabetes Mellitus, Type 2; Gliclazide; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin | 2002 |
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
Topics: Antigens; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fibrinolys | 1992 |
Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazi | 1992 |
Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com | 1992 |
[Acute pancreatitis induced by gliclazide].
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Male; Pancreatitis | 1992 |
Effect of gliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Gliclazide; Humans; In Vitro Techniques; Male | 1992 |
Thromboxane/prostacyclin balance in type II diabetes: gliclazide effects.
Topics: Diabetes Mellitus, Type 2; Epoprostenol; Gliclazide; Humans; Lipids; Thromboxane A2 | 1992 |
Gliclazide therapy of NIDDM in the 90s. Proceedings of 1st International Diamicron Symposium, September 24, 1990, Montreal, Canada.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans | 1991 |
The effect of Diamicron on the secretion and action of insulin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Secretion; Kinetics; | 1991 |
Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazid | 1991 |
Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Follow-Up Studies; G | 1991 |
Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gliclazide; Insu | 1991 |
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mel | 1991 |
Oral treatment of diabetes mellitus: the contribution of gliclazide.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans | 1991 |
Oral treatment of diabetes mellitus: the contribution of gliclazide. Proceedings of a symposium, September 23, 1989, Lisbon, Portugal.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Gliclazide; Humans | 1991 |
Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Insulin; Insulin In | 1991 |
An evaluation of long-term glycemic control in non-insulin-dependent diabetes mellitus: the relevance of glycated hemoglobin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Huma | 1991 |
Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide.
Topics: Animals; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Ani | 1991 |
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Male; | 1991 |
1H nuclear magnetic resonance and clinical studies of interaction of calcium antagonists and hypoglycemic sulfonylureas.
Topics: Adenosine Triphosphate; Aged; Binding Sites; Blood Glucose; Calcimycin; Calcium; Chromatography, Gas | 1991 |
The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Gliclazide; Humans; Insulin | 1990 |
The effect of timing on gliclazide absorption and action.
Topics: Absorption; Adult; Aged; Diabetes Mellitus, Type 2; Female; Food; Gliclazide; Humans; Male; Middle A | 1990 |
[Spectrum of erythrocyte membrane lipids in various types of hypoglycemic therapy].
Topics: Biguanides; Cholesterol; Chromatography; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Female; Gl | 1990 |
Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide).
Topics: Aged; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Middle Aged; Sulfonylurea Compoun | 1989 |
Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.
Topics: Animals; Animals, Newborn; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellit | 1989 |
Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients.
Topics: ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Gliclazide; Glucose; Glycogen Synthase | 1989 |
Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gliclazide; Glucose Clamp Techniqu | 1989 |
The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.
Topics: Adult; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Insulin; Insulin Sec | 1989 |
Gliclazide alcohol flush.
Topics: Chlorpropamide; Diabetes Mellitus, Type 2; Ethanol; Flushing; Gliclazide; Humans; Male; Middle Aged; | 1989 |
Effect of sulphonylurea administration on insulin secretion and amino acid metabolism in non-insulin-dependent diabetic patients.
Topics: Adult; Aged; Amino Acids; Amino Acids, Branched-Chain; Blood Glucose; Diabetes Mellitus, Type 2; Fem | 1985 |
Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Moni | 1985 |
[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; | 1988 |
Effect of gliclazide on non-insulin dependent diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Gliclazide; Glucose Tolerance Test; Humans; Insul | 1988 |
[Hemorheologic, metabolic and blood coagulation changes in diabetics in treatment with sulfanyl ureas].
Topics: Blood Coagulation; Blood Viscosity; Diabetes Mellitus, Type 2; Erythrocyte Deformability; Gliclazide | 1988 |
Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Proteins; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glyburide; Glycat | 1988 |
[Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors].
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gliclazide; Gluco | 1988 |
Plasma activity of the enzyme N-acetil-beta-glucosaminidase in healthy and diabetic subjects: effects of treatment with a sulfonylurea drug.
Topics: Acetylglucosaminidase; Adult; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1988 |
A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Insu | 1988 |
[Non-insulin-dependent diabetes and gliclazide].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Insulin Resistance; Insulin Secretion; Sulfo | 1986 |
[Gliclazide in the non-insulin-dependent diabetic patient in geriatrics].
Topics: Administration, Oral; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gli | 1988 |
New oral hypoglycemic drug--gliclazide--in the treatment of maturity onset diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male; Middle | 1988 |
[The importance of gliclazide in clinical practice].
Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Sulfonylurea Compounds | 1988 |
Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
Topics: Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Carbohydrates; | 1986 |
Gliclazide--oral hypoglycaemic agent.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Gliclazide; Humans; Sulfonylurea Compounds | 1985 |
Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Female; Gliclazide; | 1985 |
Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; | 1985 |
Gliclazide: the effects on lipids in type II diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Lipids; Mal | 1985 |